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DIRECT DIGITAL ENGAGEMENT OF PATIENTS AND
DEMOCRATIZING HEALTH CARE
Dov Greenbaum JD, PhD, CIPP/E†
Smartphones and social media have changed the way we
integrate technology into our daily lives, and this is quickly bleeding
into diverse medical fields. Many social media sites provide specialty
forums for the sick to interact with their peers. Unfortunately, these
sites are mostly unregulated environments where advertisers can prey
on the desperate but unwary, people can provide their unwarranted
but seemingly authoritative medical opinions, and clinicians can troll
for cohorts for their studies. These sites also encourage users to share
personal and private medical information; oftentimes that medical
information implicates not only the immediate patient, but also her
extended family members who might be similarly experiencing, but
more privately, the same or similar medical conditions.
Just like social media brings medical consultancy to the masses,
smartphones have brought medical diagnostics to just about anyone
who can download a mobile device software application (app).
Diagnostic and other medical apps often take advantage of the evershrinking size of wearable technologies, as well as advances in
computing that can offer doctors, patients, and third parties powerful
medical tools on their portable computing devices.
The FDA has provided little to no guidance in the Wild West of
patient related social media sites. Although it has issued voluntary
guidelines for apps intended to diagnose, treat, or prevent diseases
many questions remain unanswered. Without clear rules for these
relatively new classes of medical devices, and with the threat of
regulatory and monetary repercussions for app developers, the FDA
may be chilling development of new and useful medically related
applications.
Both patient-oriented social media sites and many mobile
medical applications (MMAs) are particularly useful and relevant for
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the growing class of chronically ill patients. While the potential for
heavy-handed regulation of MMAs may chill development in this area
and hurt this aforementioned population, the lack of any oversight in
patient oriented social media sites may also potentially harm this
demographic by not enforcing any filter to a largely lay and
desperate population.
This paper will provide brief reviews of the state of the art for
these medically related technologies and review the regulatory and
legal aspects of these similar but distinct technologies. The paper will
suggest both a hybrid regulatory and technological solution for
MMAs and a mostly-regulatory solution for policing patient oriented
social media sites. These proposed rules will also take into account
related issues such as evolving social norms, including the rapid rise
of the quantified-self-trend and changes in perceptions of privacy.
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INTRODUCTION
Historically, the Internet and related technologies helped to
democratize many aspects of society. This was, and continues to be
the case with healthcare. Traditionally, medicine was a paternalistic
profession that actively promoted God-complexes amongst its
practitioners.1 These and other high barriers to entry limited the
practice of medicine and the development of medical devices to the
professionals and to corporations with, or with access to, deep
pockets.
Now, anyone who can program a smartphone or tablet
application (app) can potentially produce a medical device. Similarly,
social media sites aimed particularly at patient populations have
empowered patients to help each other and provide additional
important care and support, and perhaps surprisingly, useful clinical
data. Both concurrent advances in the democratization of health care
have the potential to provide substantial benefit. Both, however, also
raise a number of serious concerns.
The first part of this paper will suggest a less nuanced and more
novel approach to mobile health (mHealth) taxonomy than
predecessor papers. This relatively simple approach will be dictated
principally by the goal of promoting innovation without jeopardizing
safety. This paper argues that under the current and proposed regimes,
innovation is not promoted2 and safety is actually jeopardized.
The second part of the paper will provide arguments as to why
even those applications that taxonomically typically fall in what
should be an unregulated group of apps really require a hybrid
regulatory and technological solution to promote innovation while
simultaneously helping and protecting an ever growing demographic.
In the third section, this paper will segue to social media sites
aimed at patient subgroups, describing and defining them in detail.
The fourth section will raise real and relevant concerns with regard to
patient oriented social media sites and suggest a mostly regulatory fix.
The final section will provide conclusions.
Notably, this paper hopes to be ahead of the curve regarding the
issues raised. As such, data relating to some of the concerns described
1. Maureen Dowd, Decoding the God Complex, N. Y. TIMES (Sept. 28, 2011), available
at http://www.nytimes.com/2011/09/28/opinion/dowd-decoding-the-god-complex.html.
2. Marsha Blackburn, et al., Letter From Congressional Representatives to the Food &
Drug Admin. and the Fed. Trade Comm’n, U.S. CONGRESSMAN MARSHA BLACKBURN (Apr. 3,
2012),
http://blackburn.house.gov/uploadedfiles/letter_from_congress_to_fda_and_fcc__
3apr2012.pdf.
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herein may be sparse at best.
I. MOBILE MEDICAL APPLICATIONS
Under Section 201 of the Federal Food, Drug, and Cosmetic Act,
a device is “an instrument, apparatus, implement, machine,
contrivance, implant, in vitro reagent, or other similar or related
article, including any component, part, or accessory, which is...
intended for use in the diagnosis of disease or other conditions, or in
the cure, mitigation, treatment, or prevention of disease, in man or
other animals.”3 The U.S. Food and Drug Administration (FDA) has,
on a number of occasions, decided that the “intended use clause”
includes software; for example, mobile medical applications (MMAs)
fall under FDA purview as medical devices.4,5
The relatively recent term “mHealth” relates to both mobile
health portable electronics software applications and related and/or
unrelated appliances.6 This paper focuses on the former—mobile
medical applications (MMAs) in FDA parlance. Their closely related
counterparts, mobile health applications (MHAs),7 will be subsumed
under the MMA heading. Currently, most MMAs are classified as
Class II devices under current FDA guidelines, i.e., “higher risk
devices than Class I that require greater regulatory controls to provide
reasonable assurance of the device’s safety and effectiveness.”8

3. 21 U.S.C. § 321(h) (2012).
4. U.S. Food & Drug Admin., Mobile Med. Applications: Guidance For Indus. & FDA
http://www.fda.gov/downloads/
Staff, U.S. FOOD AND DRUG ADMIN., (Feb. 9, 2015),
MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM263366.pdf.
5. Suzan Onel, Where the “App” World and FDA Collide: Current Status of the FDA’s
Regulation of Medical Device Software and Mobile Medical Apps, in INSIDE THE MINDS,
RECENT DEVS. IN FOOD & DRUG LAW 153, 155 (2014), http://www.klgates.com/files/
Publication/7642d9b2-62b4-45ff-bf9e-7aa2ad4a7496/Presentation/PublicationAttachment/
af8747a0-a280-4d16-8f8c-7b4a48de30a0/Inside_the_Minds_Onel_Chapter.pdf
6. See Anne Marie Helm & Daniel Georgatos, Privacy and mHealth: How Mobile
Health “Apps” Fit Into a Privacy Framework Not Limited to HIPAA, 64 SYRACUSE L. REV.
131, 134 (2014), for a definition of mHealth (“[W]hen a provider of healthcare services uses
connected and interactive mobile computing4 to produce, access, transmit, or store data for the
provision of healthcare services to patients, or when a patient or consumer uses connected and
interactive mobile computing to produce, access, transmit, store, or otherwise share data for a
health-related purpose.”).
7. Ceara Treacy et al., Mobile Health & Med. Apps: Possible Impediments to
Healthcare Adoption, in PROC. OF THE SEVENTH INT’L CONF. ON EHEALTH, TELEMEDICINE, &
SOCIAL MEDICINE 199, 199 (Marike Hettinga et al. eds., 2015).
8. U.S. Food & Drug Admin., What Does it Mean for FDA to “Classify” a Medical
Device?, ABOUT FDA (Dec. 28, 2015), available at http://www.fda.gov/AboutFDA/
Transparency/Basics/ucm194438.htm.
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There has been a rapid growth of health-related applications for
online platforms.9 According to at least one study, by 2015 there were
over 165,000 mobile health apps available for users to download.10
According to another study, the market for mHealth apps will reach
$26 billion globally by 2017.11 Further, another recent survey
suggests that at least 10% of the US population have already
downloaded an mHealth application and another 46% would be
interested in using the technology to monitor and manage health vitals
and other health-related data.12
Actual efforts to track the types of mHealth apps available on the
myriad of mobile platforms available to users today, estimated at over
40,000,13 including smartphones, tablets, phablets and the like, seem
reminiscent (in retrospect) of the sad efforts to catalogue the internet
in the early days of the World Wide Web. With development of
mHealth apps rapidly increasing, and with new apps appearing almost
daily and older apps falling out of use, these efforts seem, by their
very nature, Sisyphean.
These impressive numbers notwithstanding, the medical
community still knows very little about the uptake and overall
actionable usage of mHealth despite the large number of studies in the
field.14
In general, these health-related applications for mobile
technology fall under the rubric of Health IT. Under current law, three
“agencies,” including: the Food and Drug Administration (FDA), the
Office of the National Coordinator for Health Information
Technology (ONC) and the Federal Communications Commission

9. Eric Topol, The Future of Medicine Is in Your Smartphone, WALL ST. J. (Jan. 9,
2015), available at http://www.wsj.com/articles/the-future-of-medicine-is-in-your-smartphone1420828632.
10. IMS Institute, Patient Adoption of mHealth Use, IMS HEALTH (Sept. 2015), available
at
http://www.imshealth.com/en/thought-leadership/ims-institute/reports/patient-adoption-ofmhealth#ims-form.
11. Ralf-Gordon Jahns, The Market for mHealth App Services Will Reach $26 Billion by
2017, RESEARCH2GUIDANCE (2015), available at http://www.research2guidance.com/themarket-for-mhealth-app-services-will-reach-26-billion-by-2017.
12. Deloitte, mHealth: A Check-Up on Consumer Use, DELOITTE, http://
www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-chsmhealth-infographic.pdf.
13. Scott Rupp, mHealth Stats: Mobile Apps, Devices and Solutions, ELEC. HEALTH
REPORTER (Dec. 10, 2015), available at http://electronichealthreporter.com/mhealth-statsmobile-apps-devices-and-solutions/.
14. Mark Tomlinson et al., Scaling Up mHealth: Where is the Evidence?, 10 PLOS MED.
1 (2013).

98

SANTA CLARA HIGH TECH. L.J.

[Vol. 32

(FCC), were recently tasked with determining a “proposed strategy
and recommendations on an appropriate, risk-based regulatory
framework pertaining to health information technology, including
mobile medical applications, that promotes innovation, protects
patient safety, and avoids regulatory duplication.”15 In addition, the
Federal Trade Commission (FTC) has been cracking down on
mHealth apps.16 For example, the FTC recently fined companies with
apps that misrepresent their medical abilities, e.g., the ability to detect
cancers.17
This work will focus particularly on the FDA, which has a clear
regulatory authority over software related to medical devices.18
According to the most recent list of FDA guidance priorities, the
agency may choose to reevaluate its role in medical software, perhaps
in light of congressional efforts to cabin it.19
However, thus far, the FDA has unreservedly failed in its review
of MMAs. On average, the FDA takes 67 days to review a MMA; by
this point, the app has often been updated and likely changed such
that the initial product no longer resembles the app submitted for
review.20 Moreover, only a minute percentage of the available apps
have even been reviewed by the FDA; the majority of them have been
classified as Class II medical devices.21
Whereas most analyses of the current state of affairs for healthrelated apps tend to fault the FDA’s guidance documents for any

15. FDA SAFETY & INNOVATION ACT (FDASIA), Pub. L. No. 112-144, § 618, 126 Stat.
993 (2012).
16. See, e.g., FTC Watch, More Consumer Protection Action on the Way at the FTC,
FTC WATCH ISSUE NO. 823 (Feb. 14, 2013) available at http://ftcwatch.com/series/823.
17. Federal Trade Commission, FTC Cracks Down on Marketers of “Melanoma
Detection” Apps, PRESS RELEASES (Feb. 23, 2015), available at https://www.ftc.gov/newsevents/press-releases/2015/02/ftc-cracks-down-marketers-melanoma-detection-apps.
18. Richard A. Merrill, The Architecture of Government Regulation of Medical
Products, 82 VA L. REV. 1753 (1996).
19. See, e.g., Darius Tahir, FDA Puts Interoperability Guidance on Back Burner,
MODERN HEALTHCARE (Jan. 9, 2015), available at http://www.modernhealthcare.com/article/
20150109/NEWS/301099953.
20. Greg Slabodkin, FDA’s Bakul Patel: For Mobile Medical Apps, Patient Safety First,
FIERCE
MOBILE
HEALTHCARE
(May
23,
2013),
available
at
http://
www.fiercemobilehealthcare.com/story/fdas-bakul-patel-mobile-medical-apps-patient-safetyfirst/2013-05-23.
21. John Avellanet, Majority of Mobile Health Apps Class II Devices for FDA,
COMPLIANCE ZEN (July 2013), available at http://www.compliancezen.com/compliance_zen/
2013/07/majority-mobile-health-apps-class-ii-devices-fda.html; see also Ting-Yu Wang et al.,
mAuditor: Mobile Auditing Framework for mHealth Applications, in PROC. OF THE 2015
WORKSHOP ON PERVASIVE WIRELESS HEALTHCARE 7, 7 (Emmanuel Baccelli et al. eds, 2015).
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number of limitations, omissions and other errors, this paper will
argue that much of the proposed FDA regulation of mHealth should
be done away with entirely, with any regulation limited to only a
small subset of apps. Under this initial proposal most consumer apps,
arguably the bulk of the current catalogue of MMAs, would remain
essentially unregulated under the FDA.
To some degree, this is the goal of the Preventing Regulatory
Overreach To Enhance Care Technology (PROTECT) Act of 201422
which ultimately was not passed.23 As per US Senator Deb Fischer’s
(R-Neb) office:
Under current law, the FDA can use its definition of a medical
device to assert broad regulatory authority over a wide array of lowrisk health IT, including mobile wellness apps, scheduling software,
and electronic health records. The PROTECT Act gives clarity to
FDA’s regulatory process to focus on products that pose a legitimate
risk to human health. This more effective, risk-based framework
boosts patient safety by prioritizing FDA’s attention to technologies
that pose the greatest health risk. It also protects low-risk health IT
from unnecessary regulatory burdens that stifle opportunities for job
creation, innovation, and improved care.24
Somewhat counterintuitively to the MMA arguments, this paper
will also argue that social media sites focused on patient groups ought
to be more regulated, albeit perhaps not by the FDA. This might even
go against conventional wisdom at the FDA, which after years of
delays,25 effectively dropped social media from its 2011 guidance
agenda,26 but later re-included it.27

22. THE PROTECT ACT, S. 2007, 113th Cong. (as introduced, Feb. 10, 2014), available
at https://www.govtrack.us/congress/bills/113/s2007/text/.
23. Id.
24. Angus King, King, Fischer Introduce Legis. to Protect Jobs, Prevent Overregulation
in Growing Health IT Industry, ANGUS KING UNITED STATES SENATOR FOR MAINE, (Feb. 10,
2014), available at http://www.king.senate.gov/newsroom/press-releases/king-fischer-introducelegislation-to-protect-jobs-prevent-overregulation-in-growing-health-it-industry/.
25. Breaking – Its Official – FDA Delaying Social Media Guidance Until at Least Q1
2011, EYE ON FDA (Dec. 2010), available at http://www.eyeonfda.com/eye_on_fda/2010/12/
breaking-its-official-fda-delaying-social-media-guidance-until-at-least-q1-2011.html.
26. FDA Drops Social Media from Its 2011 Guidance Agenda, PHARMA MARKETING
BLOG (June 1, 2011), http://pharmamkting.blogspot.com/2011/06/fda-drops-social-media-fromits-2011.html.
27. U.S. Food & Drug Admin., Guidance Agenda: New & Revised Draft Guidances
CDER is Planning to Publish During Calendar Year 2016, U.S. FOOD AND DRUG ADMIN. (Jan.
22, 2016), http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM417290.pdf
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A. MMA Taxonomy
Taxonomies have been developed in an attempt to catalogue the
wide array of potentially regulatable mobile medical applications,28
including a taxonomy by the FDA itself that confusingly makes an
important practical distinction between those apps that pose “a risk to
patients” and those apps that “pose a low risk to patients,” a
distinction poorly clarified in the FDA’s appendix to their guidance
documents.29
The Food and Drug Administration Safety and Innovation Act
(FDASIA) “expands the FDA’s authorities and strengthens the
agency’s ability to safeguard and advance public health.”30 Included
in this authority, a workgroup was “ charged with providing expert
input on issues and concepts identified by the Food and Drug
Administration (FDA), Office of the National Coordinator for Health
IT (ONC), and the Federal Communications Commission (FCC) to
inform the development of a report on an appropriate, risk-based
regulatory framework pertaining to health information technology
including mobile medical applications that promotes innovation,
protects patient safety, and avoids regulatory duplication.”31 But even
the FDASIA working group’s more fleshed-out stratification of risk
does not take into account many of the concerns raised herein with
regard to concerns with MMAs.32
While some of these taxonomies attempt to place each individual
type of application into its most relevant and distinctive classification,
this paper proposes perhaps a crude and consequentially more useful
taxonomy.
A binary taxonomy is particular useful, if not actually necessary,
and is even more simplistic than the current FDA April 2014

28. See, e.g., Miloslava Plachkinova et al., A Taxonomy of mHealth Apps—Security and
Privacy Concerns, in PROC. OF THE 2015 48TH HAW. INT’L CONF. ON SYS. SCIENCES (HICSS)
3187, 3187 (Tung X. Bui et al. eds., 2015).
29. U.S. Food & Drug Admin., supra note 4, at 23.
30. U.S. Food & Drug Admin., Food and Drug Administration Safety and Innovation
Act, REGULATORY INFORMATION (Oct. 6, 2015), available athttp://www.fda.gov/
RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/
ucm20027187.htm.
31. HealthIT.gov, FDASIA, HEALTHIT.GOV (June 17, 2015), available at https://
www.healthit.gov/facas/health-it-policy-committee/hitpc-workgroups/fdasia.
32. Sarah P. Slight & David W. Bates, A Risk-Based Regulatory Framework for Health
IT: Recommendations of the FDASIA Working Group, 21 J. AM. MED. INFORMATICS ASS’N, No.
e2, 2014, at e181-4.
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recommendations.33 Many software developers in the mHealth field
may simply be startups34 that are not as savvy to FDA regulation and
oversight as their more experienced medical device manufacturer
counterparts; as such they may be discouraged from innovating in this
area if they lack the ability to relatively easily assess their regulatory
environment from the outset.35 This is particularly problematic given
that in many cases the FDA has reverted to applying its standard
medical device methodologies in assessing MMAs.36
The goal of this effort would be to simplistically divide apps into
manageable categories that reflect the subsequent nature of their
regulation. The more basic the divisions, the easier they are to apply,
particularly for the uninitiated. And the less likely that the uninitiated
startup innovators in this field will be confused, the less likely
innovation will be chilled. For example, given that Class II devices
face increased regulations and costs of doing business,37 MMA
developers will want to know beforehand, or before huge expenses
have been sunk, whether they fall into a class associated with high
costs or a class associated with low regulatory costs.
mHealth is particularly being pursued aggressively by startups
that are relatively FDA-naïve. For example, venture capital investors
have pumped more than a quarter billion dollar in the start of 2013
into mHealth.38 Even with the need for regulatory oversight, the FDA
should be careful to promote rather than inhibit innovation in this area

33. U.S. Food & Drug Admin., FDASIA Health IT Report, ABOUT FDA (April 21, 2014),
available
at
http://www.fda.gov/AboutFDA/CentersOffices/
OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm390588.htm.
34. See, e.g., MHEALTH STARTUPS, https://angel.co/mhealth (last visited Jan. 10, 2016);
MHEALTH,
https://www.crunchbase.com/category/mhealth/
a3b491d88d66b566a059c14322895d77 (last visited Jan. 10, 2016); MOBIHEALTHNEWS, http://
www.mhealthnews.com/blog/42-startups-cusp-mhealth-innovation (last visited Jan. 10, 2016);
ROCK HEALTH https://rockhealth.com/reports/digital-health-2015-midyear/ (last visited Jan. 10,
2016);
STARTUP HEALTH INSIGHTS https://www.startuphealth.com/content/insights-2015q2 (last
visited Jan. 10, 2016).
35. Robert L. Garrie & Pamela E. Paustian, mHealth Regulation, Legislation, and
Cybersecurity, in MHEALTH 45, 45 (Springer US, 2014).
36. Vanessa Coleman, FDA Approved?: Examining the FDA’s Approach to Mobile
Medical Apps and its Sufficiency, LAW SCHOOL STUDENT SCHOLARSHIP SETON HALL LAW
(2015),
http://scholarship.shu.edu/cgi/viewcontent.cgi?article=1681&context=student_
scholarship.
37. Avellanet, supra note 21.
38. Nanette Byrnes, Mobile Health’s Growing Pains, MIT TECH. REVIEW (July 21,
2014), available at http://www.technologyreview.com/news/529031/mobile-healths-growingpains/.
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as it has already been shown that mHealth apps are beneficial in the
health care environment, allowing for more rapid and accurate health
care decisions by health care providers.39
To this end, this paper argues for a dualistic regulatory oversight
test. An application necessitates some form of regulatory oversight by
the FDA when: (1) a mHealth app is configured and/or otherwise
designed to be used in a clinical environment [e.g., in conjunction
with electronic health records (EHRs) such as in a doctor’s office,
ambulance, clinic, or hospital] and (2) that application uses one or
more sensors (onboard and/or external) to perform a calculation based
on data obtained in real or near-real-time from the patient, her
hospital bed or other patient related data. This is slightly broader than
the FDA’s own regulatory system which, while seeming very broad in
applying its oversight to mainly those apps “whose functionality
could pose a risk to patient safety if the [MMAs] were not to function
as intended,”40 is in practice very narrow. The extent of that
regulatory control should be related to the destined usage of the
application and the nature of the application. The regulation of these
apps should include a standardization of data collection and storage,
as well as standardized application program interfaces (APIs), so that
different apps can easily and coherently communicate with each
other.
All other mHealth apps, such as consumer directed apps, do not
need any regulatory oversight whatsoever by the FDA. However, they
must be clearly marked as being recreational/non-clinical to ward off
this proposed governmental oversight. In this sense, the application
must also not make any clinical claims related to its utility, or market
itself as such. This clear demarcation might include a clickwrap
agreement, and/or a perpetual clickwrap feature in which the user
must click through a simple statement noting the limited (i.e.
recreational) use of the application every time the user employs the
application. This suggestion follows conventional wisdom wherein
nearly a third of correspondents to a 2013 Deloitte survey believed
that mobile applications are likely to have potential errors.41 And in

39. Mirela Prgomet et al., The Impact of Mobile Handheld Technology on Hospital
Physicians’ Work Practices and Patient Care: A Systematic Review, 16 JOURNAL OF THE
AM. MED. INFORMATICS ASS’N 792, 792 (2009); Lex van Velsen et al., Why Mobile Health
App Overload Drives Us Crazy, and How to Restore the Sanity, MED. INFORMATICS &
DECISION MAKING, NO. 23, 2013, at 1 (2013).
40. U.S. Food & Drug Admin., supra note 4, at 4.
41. Deloitte, supra note 12.
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any event, it would be unfeasible for any government organization to
effectively police and regulate the growing ranks of mHealth apps,
particularly in light of the above concerns. Moreover, in addition to
the errors, there are other legitimate health-related concerns for
consumer-facing applications, such as over-reliance on non-human
analysis and the inability of many of the applications to find
secondary medical problems that might otherwise be discovered in a
face-to-face doctor visit.42
The types of apps that would fall under the regulation-free
designation would include many of those that are, or could be,
regulated by the FDA as proposed under their guidance documents.
B. Why MMAs Should Not Be Marketed As Medical Devices
Not only must mHealth applications for use in clinical settings
be regulated, they actually ought to be regulated and consistently
monitored. The nature of the technology demands such oversight. For
instance, consider the following scenario. There are hundreds of
millions of smartphones in the world with a myriad number of distinct
and diverse models running a wide variety of operating systems and
their respective versions. Data from 2013 suggests that only about 4%
of all Android mobile phones and devices were running the most upto-date version of the operating software; the rest were running any
number of other variations, which does not include the multitude of
free and/or otherwise applications on these devices that alter basic
operating aspects of the phone either unintentionally or even
maliciously.43
Each smartphone contains a number of sensors, i.e., a sensor
being something that measures a physical quantity and converts that
physical quantity into a digital or analog signal that can be read by the
onboard processing hardware, including those that measure motion,
orientation, and environmental conditions. These sensors can be
hardware, software, or a hybrid of the two.
“Hardware-based sensors are physical components built into a
handset or tablet device. They derive their data by directly measuring
specific environmental properties, such as acceleration, geomagnetic
field, strength, or angular change. Software-based sensors are not

42. Stephen McInerney, Can You Diagnose Me Now? A Proposal to Modify the FDA’s
Regulation of Smartphone Mobile Health Applications with a Pre-Market Notification and
Application Database Program, 48 U. MICH. J.L. REFORM 1073, 1079 (2015).
43. MARC GOODMAN, FUTURE CRIMES: EVERYTHING IS CONNECTED, EVERYONE IS
VULNERABLE AND WHAT WE CAN DO ABOUT IT 107 (2015).
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physical devices, although they mimic hardware-based sensors.
Software-based sensors derive their data from one or more of the
hardware-based sensors and are sometimes called virtual sensors or
synthetic sensors. The linear acceleration sensor and the gravity
sensor are examples of software-based sensors.”44
Motion sensors can include gravity sensors, accelerometers,
linear acceleration sensors, rotational vector sensors tracking chips
(which can distinguish between a phone holder’s walking and
driving) and gyroscopes. Orientation sensors can include geomagnetic
field sensors, positional sensors, global positioning sensors and the
like. Environmental sensors can include infrared, force, ambient air
temperature sensors and local air pressure sensors. Additionally,
environmental sensors can include proximity, illumination, and
humidity sensors. Also included in the group of environmental
sensors are photometers, barometers, and thermometers.45
Other onboard sensors include microphones and pedometers.
The increasingly powerful cameras on smartphones are also useful
sensors. Many recent models of smartphones also include fingerprint
sensors. Some phones even include sensors that can detect harmful
radiation. All in all, these sensors can have various distinct operating
parameters including different ranges, power requirements, and varied
resolution abilities.
Each smartphone model could potentially have a distinct set of
sensors and each of these sensors may interact differently (albeit
sometimes minimally so) with the wide variety of operating systems
and their respective versions: “Note: Android does not require device
manufacturers to build any particular types of sensors into their
Android-powered devices, so devices can have a wide range of sensor
configurations.”46
Downloaded software, not to mention malicious code, could
affect the way sensors read physical quantities. In some examples,
this affect could be imperceptible yet nevertheless actionable.
Additionally, even smartphone protective cases may affect the
onboard sensors, if only minimally, not to mention the various bumps
and bangs typical of the daily wear and tear on a smartphone. For
example, it has been shown that something as seemingly benign as

44. SENSORS OVERVIEW, http://developer.android.com/guide/topics/sensors/sensors_
overview.html (last visited Oct. 24, 2015).
45. Id.
46. Id.
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prolonged exposure to refrigerator magnets can decalibrate some
smartphone magnetometers.
Given all this variability it would seem nearly impossible to
design a reliable, accurate, and medically appropriate consumer
oriented mHealth app that could take into account, in its assessment
of the patient’s health, all of the potential variability associated with
the sensors and the resulting data they collect. Uncalibrated,
smartphone sensors are often error prone and unreliable for a number
of tasks.47, 48 Even with minute changes, we run the risk of potentially
drastically different and potentially misguided results that could
wrongly direct an individual concerned as to their health.
To deal with all of this uncertainty some have suggested the
mHealth applications rely only on a subset of sensor data from
smartphones such as subset of sensors that are onboard trusted
sensors, e.g., “sensors whose readings cannot be easily manipulated
by the smartphone’s OS or by applications.”49 However, these trusted
sensors may represent only a small subset of onboard, useful, and/or
relevant sensors.
Under any regulatory regime, the reliability of the application
might need to be reassessed after each and every operating system
upgrade or patch, or application software upgrade, and for each new
model and their respective subtypes. For these reasons alone, it would
seem to be prudent for the FDA to keep a close regulatory eye on
mHealth apps to confirm that each one is constantly updated to
account for changing technology. But, for these same reasons, it
would be nearly impossible for the FDA to keep tabs on all of the
direct to consumer products and all their iterations that might be
developed to deal with all of the software and hardware changes and
versions.
“The FDA is woefully understaffed and under-resourced to
oversee these things, particularly given the number of the thousands
of apps that are [most likely] under FDA’s jurisdiction.”50 This is

47. Antonio Villasante & Cristina Fernandez, Measurement Errors in the Use of
Smartphones as Low-Cost Forestry Hypsometers, 48 SILVA FENNICA, NO. 5:1114, 2014, at
1.
48. JEFFREY R. BLUM ET AL., Smartphone Sensor Reliability for Augmented Reality
Applications, Mobile and Ubiquitous Systems, in MOBILE & UBIQUITOUS SYSTEMS:
COMPUTING, NETWORKING, AND SERVICES, 127-38 (2013).
49. Alec Wolman et al., Using Trusted Sensors to Monitor Patients’ Habits, MICROSOFT
RESEARCH (2010), http://research.microsoft.com/en-us/um/people/alecw/healthsec-2010.pdf.
50. Bahar Gholipour, Should You Trust Health Apps on Your Phone? LIVE SCIENCE (July
25, 2014), available at http://www.livescience.com/47021-health-apps-fda-regulation.html
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compounded by the sheer number of users who are likely to use this
software, with some estimates suggesting that there could be more
than one and half billion users worldwide by 2018.51 With such
staggering numbers, and the ability to easily provide hundreds of
thousands of copies of software to patients, even minor missteps can
have huge repercussions. In light of the common conception that the
FDA is unequipped and understaffed for these sorts of regulatory
oversight projects, some in Congress have suggested that mHealth
ought to be excluded from the FDA’s purview.52,53
C. Regulatory Oversight Should Be Constrained In Most
Situations
The quantified-self movement uses a lot of non-standardized
consumer technologies to quantify aspects of our lives, including
products like Fitbit, and Apple Health. In addition to the lack of
standardization, many of these products vary in their ability to
accurately measure different health-related data.54, 55
These
technologies and their associated apps are, in many respects, similar
to MMAs, although arguably distinct in the nature of the analysis of
the data collected by these technologies, and/or the stated uses of that
data or analyzed data56
However, without the ability to provide an absolutely clear
demarcation where quantified self apps end and mHealth apps begin a
standardized definition of what is and what isn’t a consumer mHealth
application is likely to remain elusive. Nevertheless, both types of
software apps aimed at the consumer market should be able to escape

(quoting a health law expert, Nathan Cortez, associate professor of law at Southern Methodist
University Dedman School of Law in Dallas, Texas).
51. Mary Beth Hamel et al., FDA Regulation of Mobile Health Technologies, 371 NEW
ENG. J. MED. 372, 372-79 (2014).
52. The Sensible Oversight for Technology Which Advances Regulatory Efficiency Act
of 2013 (SOFTWARE Act), H.R. 3303, 113th Cong. (1st Sess. 2013).
53. The Preventing Regulatory Overreach to Enhance Care Technology Act of 2014
(PROTECT Act), S.2007, 113th Cong. (2nd Sess. 2014).
54. Judit Takacs et al., Validation of the Fitbit One Activity Monitor Device During
Treadmill Walking, 17 JOURNAL OF SCI. & MED. IN SPORT 496-500 (2014).
55. J. Adam Noah et al., Comparison of Steps and Energy Expenditure Assessment in
Adults of Fitbit Tracker and Ultra to the Actical and Indirect Calorimetry, 37 JOURNAL OF MED.
ENG’G & TECH. 456-62 (2013).
56. U.S. Food & Drug Admin., General Wellness: Policy for Low Risk Devices Draft
Guidance for Industry and Food and Drug Administration Staff, U.S. FOOD AND DRUG ADMIN.
(Jan. 20, 2015), http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/
guidancedocuments/ucm429674.pdf.
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the need for any regulation whatsoever by making it clear that they
cannot be trusted for clinical use, for example, as described above.
This relatively simple method to clearly determine from the
outset whether or not your mHealth app will be subject to FDA
regulation (either you are Clinical or Recreational) should provide
software with the freedom to innovate unimpededly without the
overhanging fear of FDA regulations making their product
unprofitable or unmarketable.
It is important to note that under this binary taxonomy, the
important clinical innovations would not be lost. Eventually, the
relatively mature innovation that has already passed through the
general consumer recreational marketplace could be transferred to the
clinical setting once the technology is proven in the recreational
setting, and once the programmers and their backers better understand
their product. And, hopefully at this juncture, the software producers
will be better able to bring their more mature application through the
FDA regulatory process.
Much of this may become quickly moot anyway. Once the
novelty of having your smartphone conduct medical tests wears off,
mHealth developers will likely quickly appreciate the liability
concerns associated with the unknowable hardware and software with
which is their application will interact, as described above. As such,
future computational based developments will likely migrate to the
cloud where variability associated with processing can be better
limited and controlled. Further, whereas personal data collected on a
smartphone, unless encrypted, represents a significant possibility of a
breach of privacy,57 the cloud could potentially provide a safe and
secure environment for collected mHealth patient data.
Further, more astute mHealth app developers will likely pull
away completely from smartphone-based analysis (since it is too risky
given its unpredictable nature and inability to control all the moving
parts) and market more profitable, controllable and reliable standalone devices. These stand-alone devices will likely be designed to
not suffer from many of the general concerns related to using
smartphones, including, network delays, limited bandwidth,
confounding and conflicting software applications, viruses, malware,
battery life, storage capacity and the like. For example, by 2014 there
were nearly four million distinct malware software applications

57. Robert L. Garrie & Pamela E. Paustian, mHealth Regulation, Legislation, and
Cybersecurity, in MHEALTH 45 (2014).
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focused on mobile devices.58 The growth of these devices will likely
coincide with the growth of related telemedicine technologies.
Under the proposed binary taxonmy, in the end, it is likely that
the only mHealth apps that will be regulated by the FDA will be those
that in clinical settings perform “patient-specific analysis and
providing patient specific diagnosis or treatment recommendations.
Examples of mobile apps that perform sophisticated analysis or
interpret data (electronically collected or manually entered) from
another medical device include: apps that use patient-specific
parameters and calculate dosage or create a dosage plan for radiation
therapy; Computer Aided Detection software (CAD); image
processing software; and radiation therapy treatment planning
software.”59 These apps will run on stand-alone devices, designed
specifically for the health market and in particular to avoid the
uncertainties and liabilities associated with software apps running on
old, hacked or otherwise non-optimal operating systems and
technology platforms.
D. MMAs And Chronic Disease Patients
However, the underlying theories of this taxonomy fail when it
comes to mHealth-related applications for the chronic disease
demographic.60 This is a relatively large percentage of the sick
population: “In 2012, among civilian, noninstitutionalized US adults,
approximately half (49.8%, 117 million) had at least 1 of 10 selected
chronic conditions. More specifically, 24.3% had 1 chronic condition,
13.8% had 2 conditions, and 11.7% had 3 or more conditions.”61
Chronic diseases are the leading cause of morbidity and mortality in
the United States.62
Part of treating chronic diseases is the promotion of healthy

58. Lianne Caetano, Mobile Malware in 2014, MCAFFEE BLOG CENTRAL (Mar 25,
2014), http://blogs.mcafee.com/consumer/mobile-malware-2014.
59. U.S. Food & Drug Admin., supra note 4.
60. See, e.g., Christina Farr, Former Google Executive’s App Aims to Tackle Chronic
Illness, REUTERS (Oct. 28, 2014), available at http://www.reuters.com/article/2014/10/28/ushealthcare-tech-vida-idUSKBN0IH1SV20141028.
61. Brian W. Ward et al., Multiple Chronic Conditions Among US Adults: A 2012
Update, CENTERS FOR DISEASE CONTROL AND PREVENTION (April 17, 2014), http://
www.cdc.gov/pcd/issues/2014/pdf/13_0389.pdf.
62. Ctrs. for Disease Control and Prevention, Chronic Disease Overview, CHRONIC
DISEASE PREVENTION AND HEALTH PROMOTION (Feb. 23, 2016), available at http://
www.cdc.gov/chronicdisease/overview/.
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lifestyles and the self-management of the disease.63 Self-management
of chronic disease has been shown in studies to generally improve the
health of patients and reduce the need for hospitalization, which itself
exposes the patient to opportunistic infections.64 Furthermore, some
have estimated that mHealth technologies could offer 197 billion
dollars in savings over the next two decades in treating chronic
diseases.65
As such, this demographic may make up a large percentage of
the mHealth market —in the United States, 86% of health care
spending relates to the treatment of chronic disease66 and this cannot
be easily glossed over. It might include cancer, diabetes, heart
disease, chronic obstructive pulmonary disease, HIV, and even
obesity. These patients are the ones most likely to benefit from the
constant monitoring and the constant connectivity of consumer
electronics, allowing patients to self-manage their disease or provide
for the ability to have timely interventions by a health professional
when necessary,67 provided that they actually use the applications.
And, in clinical studies where chronic disease patients used mHealth
technology, benefits were seen.68
With this demographic in mind, perhaps the above proposed
taxonomy should include a hybrid group of applications that are both
clinical and consumer directed, e.g., the passive collection of clinical
or near-clinical grade data from consumer devices that can provide
63. Caroline Free, et al., The Effectiveness of Mobile-Health Technology-Based Health
Behaviour Change or Disease Management Interventions for Health Care Consumers: A
Systematic Review, 10 PLOS MEDICINE 1 (2013).
64. Kate R. Lorig, et al., Evidence Suggesting That a Chronic Disease Self-Management
Program Can Improve Health Status While Reducing Hospitalization: A Randomized Trial, 37
MEDICAL CARE 5, 5-14 (1999).
65. Robert Litan, Vital Signs via Broadband: Remote Monitoring Technologies Transmit
Savings, Enhances Lives, AT&T (Oct. 24, 2008), https://www.corp.att.com/healthcare/docs/
litan.pdf.
66. Ctrs. for Disease Control and Prevention, Chronic Disease Prevention and Health
Promotion, CTRS. FOR DISEASE CONTROL AND PREVENTION (Jan. 23, 2016) available at http://
www.cdc.gov/chronicdisease/.
67. Tara McCurdie et al., mHealth Consumer Apps: The Case for User-Centered Design,
46 BIOMEDICAL INSTRUMENTATION & TECH. 49 (2012).
68. Charlene C. Quinn et al., Welldoc™ Mobile Diabetes Management Randomized
Controlled Trial: Change in Clinical and Behavioral Outcomes and Patient and Physician
Satisfaction, 10 DIABETES TECH. & THERAPEUTICS 160, 160-68 (2008); Charlene C. Quinn et
al., Cluster-Randomized Trial of a Mobile Phone Personalized Behavioral Intervention for
Blood Glucose Control, 34 DIABETES CARE 1934 (2011); but c.f. Bree Holtz & Carolyn
Lauckner, Diabetes Management Via Mobile Phones: A Systematic Review, 18 TELEMEDICINE
& E-HEALTH 175, 175-84 (2012) (noting that many of the studies lacked the requisite statistical
rigor to come to medically relevant conclusions).
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health care professionals with timely access to relevant data.
This hybrid group would include apps directed at consumers
with chronic disease that require some form of constant monitoring.
Alternatively, this group could also include apps directed to clinical
study participants who need to track some or more of their vitals data
off-site. This hybrid group might also interface with EHRs, albeit at
home not at a health-care related institution.
But this hybrid group would also highlight many of the practical
concerns raised above that cannot be simply solved by regulation or
legislation. The need for some oversight is pressing and the drawn out
iterative process of developing internal oversight controls, conformity
assessment tools, certification and assessment schemes and general
best practices (as suggested by the April 2014 FDASIA Health IT
Report)69 will fail to meet the urgent and exigent needs of the industry
today. The same is true for IEEE and/or ISO standard proposals.70
Rather, a more technical solution may be necessary to overcome
the issues raised and given the competing interests of public policy:
dependable software with limited regulatory oversight.
E. Technological Soultions To Policy Concerns With Chronic
Disease Oriented MMAS
To this end, a potential solution for both chronic disease apps as
well as potentially even all MMAs currently regulated or otherwise
would include a software or hardware interface to technologically
deal with many of the concerns raised. This shared boundary between
apps and anything else those apps communicate with would allow for
the regulated and controlled exchange of information between any
two different components of an mHealth environment. This could
include an interface between the MMA and the underlying operating
system and hardware or the MMA and an online component.
Developed under the auspices of a Federal agency, the
middleware could be designed explicitly to deal with the many
technical and regulatory concerns raised above.
Like the
Telecommunications Act of 1996, signed into law by President Bill

69. U.S. Food & Drug Admin., FDASIA Health IT Report: Proposed Strategy and
Recommendations for a Risk-Based Framework, U.S. FOOD AND DRUG ADMIN. (Apr. 2014),
http://www.healthit.gov/sites/default/files/fdasiahealthitreport_final.pdf.
70. E.g., ISO/IEEE 11073-10418:2014 Health Informatics—Personal Health Device
Communication—Part 10418: Device Specialization—International Normalized Ratio (INR)
Monitor, INT’L ORG. FOR STANDARDIZATION (Mar. 1, 2014), available at http://www.iso.org/
iso/iso_catalogue/catalogue_tc/catalogue_detail.htm?csnumber=61897.
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Clinton, that mandated that a specific technology (colloquially known
as a V-chip) be introduced into every new television,71 smartphones
could also be required to include this middleware in all new phones
and/or software updates.
The middleware could employ one or more open APIs
(Application Programming Interface) such that any app developer
could easily write their code to gather and/or distribute sensor data
through the software interface.72 This middleware could also create
and enforce a single unified standard of sensor data such that
independent of the hardware or the software (e.g., the smartphone and
its operating system). Further, the middleware would also enforce a
standardization of values resulting from sensors that allow for
consistent readings independent of device hardware and software —
for example, all values could be required to be presented using the
metric system. Importantly, this standardization would allow for
portability across hardware and software platforms and between other
mHealth apps, something that seems to be widely lacking for most
mHealth apps.73
This middleware could also enforce a standardization of medical
information formats, limiting the usability of data that is not provided
to the middleware from an mHealth app in standard format. This
forced standardization would further promote good, reasonable and
accurate use of collected health-related data. This standardization via
the middleware could piggyback on current efforts to enforce
standards in health care. For example, EHR standards could be
imported and required for use in mHealth apps.74,75
In summary, the middleware proposed herein would be a
standardized, calibrated, uniform platform to allow a standardized

71. Telecommunications Act of 1996, Title V – Obscenity And Violence, Pub. L. No.
104-104, 110 Stat. 56 (1996).
72. See, e.g., OPEN API INITIATIVE, openapis.org (last visited Aug. 10, 2015)
(Describing how APIs form the connection between apps and third parties, and elaborating on
how vendor neutral and open APIs can increase connectivity between apps and third party apps
and/or data sources.)
73. Shoko Miyagawa et al., Data Portability in Mhealth—Can We Retain Our Life Log
When Changing Apps, Devices, or Mobile Platforms?, 143rd APHA Annual Meeting and
Exposition, APHA (Oct. 31-Nov. 4, 2015).
74. Marco Eichelberg et al., Electronic Health Record Standards – A Brief Overview,
PROCEEDINGS OF THE 4TH IEEE INTERNATIONAL CONFERENCE ON INFORMATION AND
COMMUNICATIONS TECHNOLOGY (2006).
75. A. Begoyan, An Overview of Interoperability Standards for Electronic Health
Records, PENNSYLVANIA STATE UNIVERSITY (2007), http://citeseerx.ist.psu.edu/viewdoc/
download?doi=10.1.1.131.4421&rep=rep1&type=pdf.
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communication between onboard and linked sensors and the
individual mHealth applications. It is important that this middleware
appear frictionless to the user and the developers, otherwise they will
become a burden that users will attempt to work-around.
The middleware need not be specific to consumer based mHealth
apps, and in fact, may be very useful in clinical apps as well. The
middleware could be backwards compatible to legacy devices and
constant updates would allow it to avoid becoming obsolete.76
To this end, the software might employ an onsite- or cloud based
up-to-date database of hardware and software such that the necessary
error corrections and fudge factors could be applied to varied sensor
readings such that after these algorithms would be applied, the
distinctions between all the varied types of hardware the software
would be irrelevant. All applications receiving data from this software
would start at the same baseline.
This same software could also employ regular calibrations and
system checks both periodically during runtime and perhaps always at
boot-up to confirm that the hardware has not been damaged through
regular wear and tear and that the system’s software has not been
compromised as a result of uploaded code, malicious or otherwise.
The software interface could also be written such that it would
not allow mHealth apps to circumvent it and acquire data from the
sensors directly and not through the regulatory approved interface.
Users might be given the opportunity to opt out of this limitation
provided that they provide informed consent through, for example, a
clickwrap license.77
As an additional benefit, this same middleware could also
regulate the outflow of information from the individual mHealth apps,
requiring that, for example, all mHealth collected data be encrypted
for privacy protection. This encrypted outflow would employ one or
more known encryption methodologies, i.e., limited and controlled
encryption. This limited and controlled encryption would help
promote interoperability among different devices and systems and
76. Philip A. Berstein, Middleware: a model for distributed system services, 39.2
COMMUNICATIONS OF THE ACM 86 (1996), http://delivery.acm.org/10.1145/240000/230809/
p86-bernstein.pdf?ip=129.210.115.240&id=230809&acc=ACTIVE%20SERVICE&key=
80B0E63637265656%2EC2822F75119601FF%2E4D4702B0C3E38B35%2E4D4702B0C3E38
B35&CFID=668242243&CFTOKEN=78929755&__acm__=1473981831_
09dba1f1823bd284ac448a70487df11b (describing some of the benefits of middleware,
particularly when there are many different platforms that need to interact).
77. Nathan J. Davis, Presumed Assent: The Judicial Acceptance of Clickwrap, 22
BERKELEY TECH. L.J. 577 (2007).
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network infrastructures, and in cases of emergency or legal need, it
would be clear to the necessary agencies how to decrypt the data.
Moreover, rather than relying on varying levels of encryption for each
different application, this middleware could provide up-to-date, topof-the-line encryption.
Further, software that used the mHealth app that did not encrypt
data, or prevented the middleware from encrypting the data, would
not work unless the user clicked through a sensibly composed
clickwrap license78 that made it clear that the data could only be
employed for recreational use. Similarly, a clickwrap license would
be required to be signed off on prior to sharing collected data.
Having a software solution as a required interface would limit
the necessary regulatory outlays of the regulating agency. Much of
the necessary complexity described above would, rather than being
spread across literally thousands of applications, would all reside in
one software program. Whether the application is developed by the
FDA, some other regulatory agency or commercial group is not
relevant. It is sufficient only that it would require some regulatory
oversight to confirm that it remains accurate and useful.
Pushing this idea further, one could imagine a protected
marketplace, run perhaps by the FDA and/or relevant NGO or
governmental organizations where applications designed for clinical
home use by chronic disease patients could be distributed, akin to the
Apple iTunes market place, and distinct from the more open Android
marketplaces. Like other proprietary app marketplaces, apps within
the marketplace would have to pass a minimal standard. Further
doctors could be encouraged to professionally review mHealth apps
in this chronic disease marketplace by giving them continuing
medical education (CME) credit for time spent in evaluating software.
Evaluations would not be anonymous to prevent laziness and slacking
and doctors and medical professionals would be encouraged to
provide useful feedback that could be viewed by patients within the
marketplace.
Apple’s “Health”79 (formerly Healthkit) may be the closest
approximation of this goal for their proprietary devices: “Heart rate,
calories burned, blood sugar, cholesterol — your health and fitness
apps are great at collecting all that data. The new Health app puts that

Id.
HEALTH: AN INNOVATIVE NEW WAY TO USE YOUR HEALTH AND FITNESS
INFORMATION, http://www.apple.com/ios/whats-new/health/ (last visited Oct. 31, 2015).
78.
79.
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data in one place, accessible with a tap, giving you a clear and current
overview of your health. With HealthKit, developers can make their
apps even more useful by allowing them to access your health data,
too.”80
F. Other mHealth Concerns
In addition to the regulation of health care applications, and all
concomitant bureaucracy associated with regulation, there remain a
number of generalized concerns associated with mHealth. These
concerns are not limited to the clinical apps, but are also relevant, if
not even more so, for the unregulated recreational non-clinical
applications.
Thus, even though we have argued that mHealth applications
need not necessitate FDA oversight, particularly when they are
specifically aimed at consumers and marked as recreational,
nevertheless the continued growth of the non-medical consumer
mHealth market raises a number of real and relevant concerns that
need to be addressed.
For instance, “[c]linicians and patients are adopting mobile
technologies faster than providers can protect security and privacy.
It’s time to play catch-up.”81 Additionally, “[d]ata security and patient
privacy are top issues facing everyone in the mHealth landscape, with
regulators assessing the need for more rules and oversight, lawmakers
calling on vendors to tighten data sharing practices and physicians
citing the two issues as reasons for not embracing mHealth
technology. A recent study cites the healthcare sector as the most
immature industry in terms of personal mobile device security,
endpoint compliance discovery and remediation.”82
These security concerns are nearly insurmountable within the
current status quo of cell phone usage. “Mobile phones are one of the
most insecure devices that were ever available, so they’re very easy to
trace; they’re very easy to tap.”83 Thus, it should come at no surprise

80. Id.
81. Bari Faudree & Mark Ford, Security and Privacy in Mobile Health, WALL ST. J.
(Aug. 6, 2013), available at http://deloitte.wsj.com/cio/2013/08/06/security-and-privacy-inmobile-health/.
82. Judy Mottl, mHealth Success Hinges on Security, Workflow Adaptability, FIERCE
MOBILE HEALTHCARE (October 4, 2014), available at http://www.fiercemobilehealthcare.com/
story/mhealth-success-hinges-security-workflow-adaptability/2014-10-04.
83. Evgeny Morozov, Evgeny Morozov Quotes, BRAINY QUOTE (Sept. 10, 2015),
available at http://www.brainyquote.com/citation/quotes/quotes/e/evgenymoro555021.html?ct=
Evgeny+Morozov; GOODMAN, supra note 43. But cf. Tim Cook, A Message to Our Customers,
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that smartphones are huge security risks for health-related data.
In general, privacy concerns typically go hand-in-hand with
security concerns, e.g., that someone will gain access to their personal
and/or medical data and use it for fraud and/or identity theft. The
promise to protect (and thus regulate) “security” of medical devices,
(and now apps under the MMA guidance) is even spelled specifically
in the FDA mission statement.84 Nevertheless, even in areas where
FDA regulation has been longstanding, there remain huge gaps in the
regulation of security protocols for software.85
Security breaches, which have doubled in past year with an
estimated 60% of android phones infected by malicious code,86 can
lead to a loss of consumer trust. 87 Even when security holes are
identified it can be difficult if not impossible to have all consumers
patch their software.
This inability to currently properly accommodate all of the
private data purportedly being generated by mHealth apps is a huge
liability for health care professionals and serves as a disincentive to
popularize potentially useful apps.
According to the National Committee on Vital and Health
Statistics (NCVHS), “the statutory public advisory body to the
Secretary of Health and Human Services on health information
policy”,88 “Health information privacy is an individual’s right to
control the acquisition, uses, or disclosures of his or her identifiable
health data. Confidentiality, which is closely related, refers to the
obligations of those who receive information to respect the privacy
interests of those to whom the data relate. Security is altogether
different. It refers to physical, technological, or administrative
safeguards or tools used to protect identifiable health data from
unwarranted access or disclosure.”89
APPLE (Feb. 16, 2016), available at http://www.apple.com/customer-letter/ (Apple’s opposition
to the FBI’s request to make a new version of the iPhone operating system).
84. U.S. Food & Drug Admin., What We Do, U.S. FOOD & DRUG ADMIN. (Dec. 7, 2015),
available at http://www.fda.gov/aboutfda/whatwedo/.
85. See Eric D. Perakslis, Cybersecurity in Health Care, 371 NEW ENG. J. MED. 395 (Jul.
31, 2014).
86. Smart Clinic, Breaking Down the mHealth Security Landscape, SMART CLINIC BLOG
(Sept. 25, 2014), http://smartclinicapp.com/breaking-mhealth-security-landscape/.
87. See Faudree & Ford, supra note 81.
88. NATIONAL COMMITTEE ON VITAL AND HEALTH STATISTICS, http://ncvhs.us/ (last
visited Oct. 31, 2015).
89. Simon P. Cohn, Recommendations Regarding Privacy and Confidentiality in the
Nationwide Health Information Network, NATIONAL COMMITTEE ON VITAL AND HEALTH
STATISTICS (June 22, 2006), available at http://www.ncvhs.hhs.gov/recommendations-reports-
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It is thought that there is a growing threat of cyberattacks
associated with medical devices putting personal and private health
information at risk for being disclosed: in this area, the FDA, which
generally includes adverse event reporting and post-approval reports
in its regulation of medical devices, lacks forward-looking approach
to protect and prevent mHealth data before the malicious events
occur. (Cybersecurity is conspicuously lacking from the MMA
guidance documents).90
The substantial amount of literature relating to the general issues
of patient privacy is one of the most pressing concerns of mHealth.
Private data in the mHealth context can be thought of as broader than
in the standard healthcare context. This is simply due to the reality
that a broader array of data can be, and is, collected by mHealth
applications. This data includes daily fitness data, exercise related
information, calorie intake data, even levels of social interaction, and
the more standard health-related information including glucose levels,
blood oxygenation levels, heart rate, breathing rates, among others.
Moreover, storing this data digitally makes it more portable and as
such more likely to move via malicious actors.
With data saved locally on the device there are a number of
opportunities for the personal health-related data to be captured and
collected. Most simplistically, phones can be misplaced or hacked, as
can large data online repositories. In fact, all the major online
repositories, i.e., cloud computing providers, have been hacked.91
This data is not only at risk for privacy breaches while it is being
collected by your smartphone using remote sensors, but it is also at
risk while it sits on the phone and while it is transit between other
systems, for example, where data is transferred wirelessly from
smartphones to third party devices or cloud resource.
Transit of health-related and other privacy data can be a
necessity, particularly for apps that require remote monitoring by
health-related professionals. Additionally, data tends to be in transit
during coordinated sharing between health care professionals that
share the patient, and with remote/cloud storage such as, for example
in commercial/consumer Personal Health Record (PHR) systems like

presentations/june-22-2006-letter-to-the-secretary-recommendations-regarding-privacy-andconfidentiality-in-the-nationwide-health-information-network/.
90. See Katherine B. Wellington, Cyberattacks on Medical Devices and Hospital
Networks: Legal Gaps and Regulatory Solutions, 30 SANTA CLARA COMPUTER & HIGH TECH.
L.J. 139 (2014).
91. GOODMAN, supra note 43, at 117.
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the now discontinued Google Health,92 Microsoft’s HealthVault,93 or
the Dossia consortium,94 or in an institutional Electronic Health
Record (EHR) System.
Data transfers between phones and other devices, including the
cloud, can be tapped and health data can be extracted and collected
for any number or reasons, including, for example, identity theft,
unauthorized access to data, or unauthorized and damaging disclosure
of otherwise private health data.95,96Transit of data also occurs via
wireless technologies such as Bluetooth and/or WiFi from wireless
sensor devices or networks, e.g., wireless medical sensor networks
(WMSNs). Data is often stolen or sniffed in transit. In some instances,
femtocells and other devices that act as wireless network extenders,
have been set up for malicious and illegal purposes. These extenders
can trick phones into thinking that they are legitimate waypoints
within the cellular network, wherein in reality they are designed to
illicitly capture data.97
In addition to the most obvious victim of leaked information, the
consumer, leaked data is also embarrassing for the corporate and
health-related bodies involved in the processing and transferring of
private patient data. Moreover, the leaking, stealing or sniffing of data
could also expose risk-averse application developers to fines and
lawsuits, thereby chilling innovation.
Guidelines could attempt to enforce encryption protocols to
protect data. However, in consumer-facing apps, this type of
enforcement is not feasible. Solutions exist, but they require the
unprecedented and unlikely cooperation of the multitudes of mHealth
app developers and/or the consumers to be implemented.98 It is

92. GOOGLE HEALTH, http://www.google.com/intl/en_us/health/about/ (last visited Oct.
31, 2015).
93. HEALTH VAULT, https://www.healthvault.com/il/en (last visited Oct. 31, 2015).
94. DOSSIA CONSORTIUM, http://dossia.org/ (last visited Oct. 31, 2015).
95. David Kotz, A Threat Taxonomy for mHealth Privacy (2011), http://
ieeexplore.ieee.org/stamp/stamp.jsp?arnumber=5716518.
96. Consumer Reports, Your Secrets Aren’t Safe: Data Thieves are After Your Most
Private Info—When You Use Wi-Fi and Shop Online, and Even When You Store Files in the
Cloud, CONSUMER REPORTS (May 2014), available at http://www.consumerreports.org/cro/
magazine/2014/07/your-secrets-aren-t-safe/index.htm.
97. Lauren Walker, Fake Cell Towers Allow the NSA and Police to Keep Track of You,
NEWSWEEK (Sept. 5, 2014), available at http://www.newsweek.com/what-cell-ls-thoseominous-phony-towers-268589; Kim Zetter, Hacker Spoofs Cell Phone Tower to Intercept
Calls, WIRED (July 31, 2010), available at http://www.wired.com/2010/07/intercepting-cellphone-calls.
98. Bruno M. Silva et al., A Data Encryption Solution for Mobile Health Apps in
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unlikely that even suggested guidelines will be headed; app
developers uninterested in the cumbersome and user-unfriendly
encryption are unlikely to impose encryption without consumer
demand. Additionally, consumers are unlikely to demand encryption
since both hardware level encryption and software level encryption
can affect phone performance and impact battery life; Google recently
disclosed that up to 95% of its unencrypted traffic comes from mobile
devices.99 Most consumers do not protect their mobile phones with
any technological protections.100, 101,102 Even consumers that encrypt
data on their own devices are unlikely to be sufficiently
technologically savvy to encrypt communications between their
applications and third parties. Moreover, the government itself is
against strong encryption for smartphone data.103, 104
Privacy concerns might also result in a chilling effect, not only in
the development of the mHealth apps and technologies, but in the
prescription of their use by doctors wary of the fines and headaches
associated with even minor HIPAA infractions.105,106 Under the
HIPAA Privacy Rule, HIPAA oversight is limited to privacy breaches
associated with Protected Health Information (PHI), which only
relates to identifiable information on an individual’s mental and/or
physical health, and only when that information is held or transmitted

Cooperation Environments, 15 J. MED. INTERNET RES. (2013).
99. GOOGLE TRANSPARENCY REPORT, https://www.google.com/transparencyreport/https
(last visited March 15, 2016).
100. Sophos, 67 Percent of Consumers Don’t Have Password Protection on Their Mobile
Phones, SOPHOS PRESS RELEASES (Aug. 9, 2011), available at https://www.sophos.com/en-us/
press-office/press-releases/2011/08/67-percent-of-consumers-do-not-have-password-protectionon-their-mobile-phones.aspx.
101. Herb Weisbaum, Most Americans Don’t Secure Their Smartphones, CNBC (Apr. 26,
2014), available at http://www.cnbc.com/2014/04/26/most-americans-dont-secure-theirsmartphones.html.
102. Donna Tapellini, Smart Phone Thefts Rose to 3.1 Million in 2013: Industry Solution
Falls Short, While Legislative Efforts to Curb Theft Continue, CONSUMER REPORTS (May 28,
2014), available at http://www.consumerreports.org/cro/news/2014/04/smart-phone-thefts-roseto-3-1-million-last-year/index.htm.
103. FBI Director Lashes Out at Apple, Google for Encrypting Smartphones, RUSSIA
TODAY (Sept. 26, 2014), available at http://rt.com/usa/190980-comey-fbi-encryption-phones/.
104. Maggie Ybarra, FBI Pushes to Weaken Cell Phone Security, Skirt Encryption, THE
WASH. TIMES (May 26, 2015), available at http://www.washingtontimes.com/news/2015/may/
26/fbi-push-to-weaken-cell-phone-security-skirt-encry.
105. See Health Information Technology for Economic and Clinical Health (HITECH)
Act, 42 U.S.C. § 1320d-5(a)(3) (2013) (describing the four-tier penalty system for HIPAA
violations).
106. Pardeep Kumar & Hoon-Jae Lee, Security Issues in Healthcare Applications Using
Wireless Medical Sensor Networks: A Survey, 12 SENSORS 55, 65-73 (2012).
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by a covered entity. Security breaches of ePHI fall under the HIPAA
security rule which sets out technical administrative and physical
standards to protect electronic persona health information.107 Under
the HITECH Act,108 breach notifications need to be provided in
instances of security failures and fines were raised significantly.
Again this is limited only to covered entities; as such HIPAA
regulations do not cover consumer directed mHealth applications.
And while HIPAA is regulated by The U.S. Department of
Health and Human Services (HHS), not the FDA,109 perhaps future
efforts can include cooperation between the FDA and HHS in battling
cyber security threats in the mHealth environment, including putting
together best practices. Until such time, consumers need to rely on
state and in some instances, federal consumer protection laws such as
those enforced by the FTC.110
In addition to privacy concerns, a particularly important issue
associated with the consumer mHealth apps is the concern that users,
lacking the proper context and technical and medical knowledge will
misunderstand or misinterpret the results, data, or information
provided by the mHealth applications.
In some examples, this might result in rash prophylactic
decisions carried out without medical supervision. These worried
well individuals,111 (iPodchondriacs112) some even clinically
hypochondriacs, might limit otherwise normal behaviors, or otherwise
act in unnecessary ways thinking that they are sick. Not only are these
people harming themselves, but they might also become a drain on
the medical system and insurers, visiting doctors and/or emergency
rooms for unnecessary checkups or procedures. Unfortunately, the
worried well are a lucrative demographic for mHealth developers, not
only will they likely purchase health-related smart phone applications,
107. Modifications to the HIPAA Privacy Rule, 67 Fed. Reg. 53,182 (Aug. 14, 2002)
(codified as 45 C.F.R. §§ 160, 164). The HIPAA Privacy Rule took effect on April 14, 2004. Id.
at 53, 183.
108. The Health Information Technology for Economic and Clinical Health Act
(HITECH) was enacted under Title XIII of the American Recovery and Reinvestment Act of
2009, Pub. L. No. 111–5, 123 Stat. 115 (2009).
109. 45 C.F.R. § 160.103.
110. Helm & Georgatos, supra note 6, at 151-67.
111. Maxine Frith, Are You One of the Rising Numbers of the ‘Worried Well’?, THE
TELEGRAPH (July 20, 2014), available at http://www.telegraph.co.uk/health/dietandfitness/
10977877/Are-you-one-of-the-rising-numbers-of-the-worried-well.html.
112. M-Health: Health and Appiness, THE ECONOMIST (Feb. 1, 2014), available at http://
www.economist.com/news/business/21595461-those-pouring-money-health-related-mobilegadgets-and-apps-believe-they-can-work.
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but it is expected that they will also purchase related peripherals that
interact or integrate with smartphones and their applications at
additional costs. Some analysts actually specifically track this
demographics’ uptake of mHealth-related technology. According to
Machina research, for example, the worried well currently account for
“61.8m connected devices in 2014 globally, increasing to more than
477m in 2023.”113
On the other side of the spectrum are the walking sick. This
demographic include groups of individuals that might otherwise need
medical care, but have been lulled into a false sense of medical
security based on results from their inaccurate or improperly used
mHealth apps. They too can be a drain on insurers and health care
providers, ignoring symptoms based on a false sense of security until
the problems become bigger, more costly and impossible to ignore.
II. DEVELOPING WORLD ACCESS TO HEALTH CARE
The pros and cons mentioned above relate primarily to the
United States and other developed nations. However, in some areas
of the world, particularly where access to healthcare is severely
limited, and outbreaks of major diseases are somewhat common,114
mHealth can be a societal boon, particularly with the burden of
chronic diseases rising in middle and low income countries.115 As
such, there have been numerous calls to scale up mHealth
technologies in these areas.116
While access to health care is limited, particularly in rural areas
of the world and in Africa, access to mobile technology, which is
more affordable than most other basic services in Africa, is on a
continual climb. Africa’s mobile subscriber growth is effectively the
fastest in the world, with estimates of over a billion mobile phone
subscribers by 2015 and mobile penetration of almost 95% of the

113. Andy Castonguay, Consumerization of Connected Health Devices Sparks Innovation
and Growing Investment, M2M NOW (May 20, 2014), available at http://www.m2mnow.biz/
2014/05/20/20697-consumerization-connected-health-devices-sparks-innovation-growinginvestment/.
114. Lizabeth Paulat, Mobile Health Apps to Become First Line of Defense in Outbreaks,
VOICE OF AMERICA (Nov. 4, 2014), available at http://www.voanews.com/content/mobilehealth-apps-to-become-first-line-of-defense-in-africa-outbreaks/2507423.html.
115. Robert Beaglehole et al., Alma-Ata: Rebirth and Revision 3-Improving the Prevention
and Management of Chronic Disease in Low-Income and Middle-Income Countries: A Priority
for Primary Health Care, 372 LANCET 940, 940 (2008).
116. See Tomlinson, supra note 14.

2015]

DIRECT DIGITAL ENGAGEMENT OF PATIENTS

121

population.117
Mobile technology may bring about significant improvements to
a healthcare system that is “constrained by high population growth,
high disease burden, inadequate workforce, widespread rural
populations and limited financial resources? The answer is mobile.”118
Mobile communications may bring a wealth of knowledge to
Africa that possesses the potential to “reimagine healthcare across
Africa.”119 “From combating malaria to detecting counterfeit drugs,
the emergence of mobile health solutions is saving more lives than
international aids.”120 In a 2013 report by PricewaterhouseCoopers,
the initiatives in Africa could potentially save a million lives by
2017.121
The mobile penetration notwithstanding, in spite of extensive
efforts,122 Africa still has the lowest rate of mHealth app adoption in
the world, and in general lower and middle income countries lag
behind their more developed neighbors.123 Perhaps the promotion of
standardized app middleware, as described above would further the
uptake of, in some instances, vital software and technologies.
However, like the concerns mentioned above, even developing
nations need to be cognizant of the particular pitfalls of mHealth
technology – particularly its limitations and unintended consequences
of too much or unclear information and data.
These same set of concerns, including privacy, security, walking
sick and worried well, exist not only in the area of mHealth, but also
in more recent developments in social media, which similarly
117. Amr Shady, Africa’s Mobile Market: Untapped Potential for Global Investment, CPAFRICA (Dec. 8, 2014), available at http://www.cp-africa.com/2014/12/08/africas-mobilemarket-untapped-potential-global-investment/.
118. Louise Bleach, How Kenya’s Mobile Apps Are Changing the Face of Africa, THE
HUFFINGTON POST: THE BLOG (July 11, 2014, 7:41 AM), http://www.huffingtonpost.com/
fueled/how-kenyas-mobile-apps-ar_b_5577233.html.
119. Seth Berkley, How Cell Phones Are Transforming Health Care in Africa, MIT TECH.
REV. (Sept. 12, 2013), available at http://www.technologyreview.com/view/519041/how-cellphones-are-transforming-health-care-in-africa/.
120. OluwaBusayo Sotunde, 10 Apps That Are Reshaping Healthcare In Africa,
VENTURES AFRICA (Nov. 23, 2014), available at http://www.ventures-africa.com/2014/11/10apps-that-are-reshaping-healthcare-in-africa/.
121. Id.
122. Jessica L. Watterson et al., Using mHealth to Improve Usage of Antenatal Care,
Postnatal Care, and Immunization: A Systematic Review of the Literature, 15 BIOMED RES.
INT’L (Jan. 22, 2015), http://www.hindawi.com/journals/bmri/2015/153402/
123. Darrell West, How Mobile Devices Are Transforming Healthcare, ISSUES IN TECH.
INNOVATION (May 2012), available at http://www.brookings.edu/~/media/research/files/papers/
2012/5/22%20mobile%20health%20west/22%20mobile%20health%20west.
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promote the sharing of personal medical data.
And, just like chronic disease patients are most likely to be major
beneficiaries in the growth of mHealth, and patient monitoring
applications, particularly those in underserved markets and countries,
so too, the growth of patient oriented social media sites are likely to
particularly help and benefit the growing population of patients with
chronic diseases and their friends, family, and loved ones.124,125 Given
all this African market is prime for the introduction of the middleware
described herein to support the nascent but growing mHealth
infrastructure. Efforts should be taken here before stakeholders
become too entrenched in their own non-standardized and
unencrypted systems.
III. PATIENT ORIENTED SOCIAL MEDIA SITES
Patient Oriented Social Media Sites (POSOMS) are social media
networks, i.e., public and private compilations of interconnected
webpages, where patients with similar diseases and/or conditions can
network. This networking differs substantially from more mainstream
sites like Facebook126 and Ello127 in that participants are not seeking
out friends but rather useful and relevant information relating to their
diseases.128
In this networking, patients (often banking on reciprocity from
fellow patients129 and related individuals) can use, for example,
associated tools and forums to help and inform each other with regard
to their disease condition. This help can include sharing physician
suggestions and rankings, as well as empirical, experimental,
experiential, and anecdotal data related to drugs, therapies, side
effects, and their referent diseases in general. This sharing of
information has been found to be helpful both for the receiving
community and also the individual sharing the information.130

124. Hamid Pousti et al., Exploring the Role of Social Media in Chronic Care
Management: A Sociomaterial Approach, 446 IFIP ADVANCES INFO. COMM. TECH. 163, 170-81
(2014).
125. Adam D. Farmer et al., Social Networking Sites: A Novel Portal for Communication,
85 POSTGRADUATE MED. J. 455, 456-58 (2009).
126. FACEBOOK, www.facebook.com (last visited Oct. 31, 2015).
127. ELLO, https://ello.co/ (last visited Oct. 31, 2015).
128. Nima Kordzadeh et al., A Multilevel Investigation of Participation Within Virtual
Health Communities, 34 COMMC’NS OF THE ASS’N FOR INFO. SYSTEMS 493, 493, 505-06
(2014).
129. Id. at 495.
130. Jeana H. Frost & Michael P. Massagli, Social Uses of Personal Health Information
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These sites, more so than standard social networking sites, also
provide often much-need emotional support from empathetic
individuals who appreciate the situation.131 These sites also allow
patients to collectively check up on and/or validate potentially useful
or damaging claims and statements related to their disease
management;132 this collaborative filtering may help protect patients
from all the disinformation online.133
In terms of patients managing their own diseases, many of these
sites provide users with proprietary symptom management tools,
medical management tools, databases of drugs and diagnostic-related
tools, among others, each used by members of the sites to varying
degrees.134 In some instances, patients can even employ these tools in
their everyday interactions with their health care providers.135
Moreover, studies suggest that whereas particularly younger kids
and teenage patients are unlikely to communicate regarding their
disease in standard social media forums like Facebook and Twitter,136
they may be more likely to do so in these specialized forums. As
such, these particular forums present a particularly important social
media safe haven for these patients. This is also the case for severely
ill patients who might not have any other regular interactions with
peers.137
These sites include Patientslikeme.com,138 CureTogether.com,139
CarePages.com,140 HealthUnlocked.com,141 Smart Patients.com,142

Within PatientsLikeMe, an Online Patient Community: What Can Happen When Patients Have
Access to One Another’s Data, 10 J. MED. INTERNET RES. (Aug. 25, 2008); Paul Wicks et al.,
Sharing Health Data for Better Outcomes on PatientsLikeMe, 12 J. MED. INTERNET RES. (June
14, 2010).
131. Kordzadeh et al., supra note 128, at 505-07.
132. Jeremy A. Greene et al., Online Social Networking by Patients with Diabetes: A
Qualitative Evaluation of Communication With Facebook, 26 J. OF GEN. INTERNAL MED. 287,
288 (2011).
133. Gunther Eysenbach, Medicine 2.0: Social Networking, Collaboration, Participation,
Apomediation, and Openness, 10 J. MED. INTERNET RES. (Aug. 25, 2008).
134. Wicks et al., supra note 130.
135. Id.
136. Maja Van Der Velden & Khaled El Emam, “Not All My Friends Need to Know”: A
Qualitative Study of Teenage Patients, Privacy, and Social Media, 20 J. AM. MED.
INFORMATICS ASS’N 16, 20 (2013).
137. See Kate Khair et al., Social Networking For Adolescents With Severe Haemophilia,
18 HAEMOPHILIA 290, 294 (2012).
138. PATIENTSLIKEME, http://www.patientslikeme.com/ (last visited Oct. 31, 2015).
139. CURETOGETHER, http://curetogether.com/ (last visited Oct. 31, 2015).
140. CAREPAGES, https://www.carepages.com/ (last visited Oct. 31, 2015).
141. HEALTHUNLOCKED, https://healthunlocked.com/ (last visited Oct. 31, 2015).
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UPOPOLIS (“a private online social network available exclusively to
pediatric patients in hospitals and care facilities”)143 and others,144
although not all are as democratic or as friendly as they make
themselves out to be. It is not clear how many of the contributing
patients and relatives appreciate and understand this.145
Some, like HealthTap.com,146 are more app than social media,
but nevertheless provide many of the same services to patients.
Others, like Ginger.io are narrowly presented as only for collecting
patient crowdsourced data.147 Still others, while providing many of
the support services, are focused solely on collecting data, not for
pharmaceutical and health-related studies, but for marketers to these
patient communities.148 And others like Treato.com, are not online
communities in and of themselves, but rather, scrapers that search the
Internet for related data and information.149
Overall the trend toward a growing number of patient oriented
social media sites seems like a positive development for patients and
their friends and families, who even in well-served markets might
otherwise not have sufficient and/or necessary access to support
groups and/or healthcare professionals on a regular basis. Even
finding medical professionals specializing in a particular disease, an
exercise that can sometimes be difficult, particularly for patients just
recently informed of their condition, can be facilitated in these
forums. Additionally POSOMS are important tools for patients to
simply collect catalogue and disseminate information about their
disease; oftentimes particularly rare diseases suffer from a lack of
accessible information.150 POSOMS can be the only lay source of
reliable information.
Moreover, these sites have the potential to provide all patients

142. SMART PATIENTS, https://www.smartpatients.com/ (last visited Oct. 31, 2015).
143. UROPOLIS, https://www.upopolis.com/ (last visited Oct. 31, 2015).
144. See, e.g., Grazia Orizio et al., The World of e-Patients: A Content Analysis of Online
Social Networks Focusing on Diseases.” 16 TELEMEDICINE & E-HEALTH 1060, 1062 (2010), for
a relatively early and lengthy list.
145. See Deborah Lupton, The Commodification of Patient Opinion: The Digital Patient
Experience Economy in the Age of Big Data, 36 SOC. HEALTH & ILLNESS 856, 866 (2014).
146. HEALTHTAP, https://www.healthtap.com/ (last visited Oct. 31, 2015).
147. GINGER.IO, https://ginger.io/ (last visited Oct. 31, 2015).
148. ALLIANCE HEALTH, https://www.alliancehealth.com/ (last visited Oct. 31, 2015).
149. TREATO, http://treato.com/ (last visited Oct. 31, 2015).
150. Kimberly K. Walker, Rare Disease-Specific Social Media Sites: An Opportunity for
Collaboration, 6 J. COMMC’N IN HEALTHCARE 71 (2013).
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with data to make better informed decisions about their health151 and/
or to share with similarly afflicted individuals other important and
relevant information about care and disease management.152, 153 And,
in general, these more informed patients can be more responsible for
their health and make more rational decisions.154 This combined with
perhaps the need for fewer in-person visits can relieve strain on a
healthcare system.155
Additionally, social relationships, be they online or in person
(although some have suggested that online networks may erode
otherwise useful real-world networks156), have been shown to have
positive effects on a patient’s condition disease management157 and
disease outcome.158,159 Conversely, the lack and/or loss of a social
network have been known to be detrimental.160, 161 These sites may
also provide the necessary incentives to mitigate attrition from the
self-monitoring apps described above.162,163 Further these sites and

151. Mario Christodoulou, Networking: The New Social Revolution in Health Care, 12
THE LANCET ONCOLOGY, 125 (2011).
152. Wicks et al., supra note 130.
153. See Noriko Hara & Khe Foon Hew, Knowledge-Sharing in an Online Community of
Health-Care Professionals, 20 INFO. TECH. & PEOPLE 235 (2007).
154. Konstantinos Bletsos et al., Towards a Fourth Cosmology of Doctor-Patient
Relationship: A Reflection on the Virtual Patient Community PatientsLikeMe, 11 TRIPLEC:
COMMC’N, CAPITALISM & CRITIQUE 136 (2013).
155. Wicks et al., supra note 130.
156. R. Mackey, Is Social Networking Killing You?, THE LEDE: THE N.Y. TIMES NEWS
BLOG (Feb. 24, 2009, 4:16 PM), http://thelede.blogs.nytimes.com/2009/02/24/is-socialnetworking-killing-you/?_r=0. But see Robert Kraut et al., Internet Paradox Revisited, 58 J.
SOC. ISSUES 49 (2002).
157. See Jingquan Li, Improving Chronic Disease Self-Management through Social
Networks, 16 POPULATION HEALTH MGMT. 285, 285-87 (2013).
158. Nicole B. Ellison et al., The Benefits of Facebook “Friends:” Social Capital and
College Students’ Use of Online Social Network Sites, 12 J. COMPUTER MEDIATED COMMC’N
1143 (2007).
159. See Eunkyung Kim et al., The Process and Effect of Supportive Message Expression
and Reception in Online Breast Cancer Support Groups, 21 PSYCHOONCOLOGY 531 (2012).
160. See Nicholas A. Christakis & Paul D. Allison, Mortality after the Hospitalization of a
Spouse, 354 NEW ENG. J. MED. 719 (2006).
161. See Julie Knoll Rajaratnam et al., The Effect of Social Isolation on Depressive
Symptoms Varies by Neighborhood Characteristics: A Study of an Urban Sample of Women
With Pre-School Aged Children, 6 INT’L J. OF MENTAL HEALTH & ADDICTION 464 (2008);
Jeffrey V. Johnson et al., Combined Effects of Job Strain and Social Isolation on
Cardiovascular Disease Morbidity and Mortality in a Random Sample of the Swedish Male
Working Population, 15 SCANDINAVIAN J. WORK, ENV’T & HEALTH 271 (1989).
162. Gunther Eysenbach, eHealth (Web-Based Behavior Change Programs) in the Toronto
Star, GUNTHER EYSENBACH’S RANDOM RESEARCH RANTS (Nov. 17, 2008), http://gunthereysenbach.blogspot.com/2008/11/ehealth-web-based-behavior-change.html.
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associated social networks allow patients to develop positive selfimages in relation to their disease.164
Patient oriented social media sites can also be particularly
powerful for the underserved. In many instances socially and/or
culturally disadvantaged patients may have trouble following and
interacting with medical professionals in an office setting, but may
find it easier to interact online in a more relaxed setting with
computing tools that provide quick translation or definitions of
complicated jargon.
A. Concerns With Patient Oriented Social Media Sites
While POSOMS have been around for at least a decade, there
remain a number of interesting heretofore unanswered research
questions, including: (1) how do these networks affect health-related
decisions; (2) to what extent do different individuals on these
networks influence patients, individually and collectively; (3) what is
the role of a physician and other healthcare workers vis-à-vis these
sites; and (4) how does activity on these sites affect patient-healthworker relationships offsite?165 Additionally, are patients being
exploited by these sites or others trolling the sites?166
1. Patient Privacy
A particularly pertinent issue relates to patient privacy on these
websites.167 Patients on these sites are encouraged to share their
data.168, 169 While privacy is a general concern online, and particularly
in social media, where simply tracking someone’s seemingly benign
“likes” and/or status updates can identify and characterize her,170

163. But see Cory A. Heidelberger et al., Online Health Social Networks and Patient
Health Decision Behavior: A Research Agenda, IEEE COMPUTER SOCIETY (2011), https://
www.computer.org/csdl/proceedings/hicss/2011/4282/00/07-05-09.pdf.
164. See Greene et al., supra note 132.
165. Heidelberger et al., supra note 163.
166. Natasha Singer, When Patients Meet Online, Are There Side Effects?, N.Y. TIMES
(May 29, 2010), available at http://www.nytimes.com/2010/05/30/business/30stream.html?_
r=0.
167. Jingquan Li, Privacy Policies for Health Social Networking Sites, 20 J. AM. MED.
INFORMATICS ASS’N 704 (2013).
168. Deborah Lupton, The Commodification of Patient Opinion: The Digital Patient
Experience Economy in the Age of Big Data, 36 SOCIOLOGY HEALTH & ILLNESS 856 (2014).
169. Katherine C. Chretien & Terry Kind, Social Media and Clinical Care Ethical,
Professional, and Social Implications, 127 CIRCULATION 1413 (2013).
170. Golnoosh Farnadi et al., Recognising Personality Traits Using Facebook Status
Updates, in Proceedings of the Workshop on Computational Personality Recognition
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these concerns are exacerbated in POSOMS where a patient’s guard
may be down in a seemingly safe environment171 and where they
might tend to share more personal and health-related information than
they might otherwise on non-health-related websites. It takes very
little information to deanonymize someone’s online profile, as was
recently shown when Netflix’s anonymous database of movie
preferences was deanonymized when the provided anonymous
information was cross-referenced with the IMDB database.172
Similarly, one’s anonymous POSOM profile may be deanonoymized
by comparing it to, say, a database of Facebook profiles.
There is also the possibility that a patient’s disclosure on these
sites, or even simply her membership on the site, could affect her or
her close families’ ability to obtain health and/or life insurance a job
and a relationship.173,174 It remains unclear as to how the Genetic
Information Nondiscrimination Act (GINA) would prevent employers
and health care providers from using information freely shared on
these sites – even anonymous sharing that might be relatively easily
deanonymized.175 SNOPA, the Social Networking Online Protection
Act, was an effort to plug some of these gaps. It has so far been
unable to become law.176
2. Defamation
Many patients feel that these sites are safe havens for
communicating otherwise sensitive and stigmatizing information.177
This feeling of a safe haven combined with the desire to share

(WCPR13) at the 7th International AAAI Conference on Weblogs and Social Media (2013);
Michal Kosinski et al., Private Traits and Attributes are Predictable From Digital Records of
Human Behavior, 110 PROC. NAT’L ACAD. SCI. 5802 (2013); Yoram Bachrach et al.,
Personality and Patterns of Facebook Usage, in Proceedings of the 3rd Annual ACM Web
Science Conference (2012); Dejan Markovikj et al., Mining Facebook Data for Predictive
Personality Modeling, in Proceedings of the 7th International AAAI Conference on Weblogs
and Social Media (2013).
171. See Li, supra note 157.
172. Arvind Narayanan & Vitaly Shmatikov, Robust De-Anonymization of Large Sparse
Datasets, in 2008 IEEE Symposium on Security and Privacy (2008).
173. See Van Der Velden & El Emam, supra note 136.
174. Daniel J. Solove, The End of Privacy?, 299 SCI. AM. 100 (2008).
175. Sandra Soo-Jin Lee & Emily Borgelt, Protecting Posted Genes: Social Networking
and the Limits of GINA, 14 AM. J. BIOETHICS 32 (2014).
176. Social Networking Online Protection Act, H.R. 5050, 112th Cong. (2012); Social
Networking Online Protection Act, H.R. 537, 113th Cong. (2013). These acts died in committee,
see, e.g., https://www.govtrack.us/congress/bills/112/hr5050.
177. Jacqueline L. Bender et al., Seeking Support on Facebook: A Content Analysis of
Breast Cancer Groups, 13 J. MED. INTERNET RES., Jan.–Mar. 2011.
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relevant information online described above can also lead to
actionable defamation of doctors and health care workers.178 As per
the Restatement (Second) of Torts (1977), “[t]o create liability for
defamation there must be: (a) a false and defamatory statement
concerning another; (b) an unprivileged publication to a third party;
(c) fault amounting at least to negligence on the part of the publisher
[with respect to the act of publication]; and (d) either actionability of
the statement irrespective of special harm or the existence of special
harm caused by the publication.”179
Further, “[a] communication is defamatory if it tends so to harm
the reputation of another as to lower him in the estimation of the
community or to deter third persons from associating or dealing with
him.”180 Most social media sites, including POSOMS, can be
described as public forums, and like their offline counterparts,
members have to be cognizant of the limitations of their speech.
Members on POSOMS face even greater dangers than standard
run-of-the-mill social media sites which themselves suffer from the
lack of fail safes (e.g. time and editors) that typically protect
individuals in offline public forums from defaming and/or libeling
individuals.181 Moreover, patients may feel that the information that
they are presenting regarding a healthcare worker will help other
patients and as such might be more likely to post something
defamatory as a result than on other social media sites. Note that
while defamation can be found by a court even when the defamatory
statement is phrased as an option, many states provide laws and antiSLAPP statutes that protect some forms of speech when the speech
was without malice and when it was believed to be true.182
Even pharmaceutical companies can sue for libel and/or
defamation for online defamatory and/or libelous comments, a likely
occurrence on these sites where patients may be advising other

178. Brian Chou and Walt Mayo, ‘I was Dissed on Angie’s List,’ REVIEW OF OPTOMETRY
(April 15, 2009), available at https://www.reviewofoptometry.com/article/i-was-dissed-onangies-list; Nicolas P. Terry, Fear of Facebook: Private Ordering of Social Media Incurred by
Healthcare Providers, 90 NEB. L. REV. 703 (2012).
179. RESTATEMENT (SECOND) OF TORTS § 558 (1977).
180. Id. § 559.
181. Ian Burrell, Libel Cases Prompted by Social Media Posts Rise 300% in a Year,
INDEP. (Oct. 19, 2014), available at http://www.independent.co.uk/news/uk/home-news/libelcases-prompted-by-social-media-posts-rise-300-in-a-year-9805004.html.
182. Elec. Frontier Found., Online Defamation Law, ELECTRONIC FRONTIER
FOUNDOUNDATION available at, https://www.eff.org/issues/bloggers/legal/liability/defamation.
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patients. 183 However, at least in the United States, under the
Communications Decency Act of 1996, the social media network
itself is likely immune from defamations made by members or third
parties,184 leaving behind few deep pockets to sue.185
In some instances where it might be obvious that the putatively
defamatory comment is an opinion, the individual publishing the
opinion may also not be liable.186 Thus, when “a “reasonable reader
would not view the blanket, unexplained statements at issue as
“facts,” [rather...] subjective speculation’ or “merely rhetorical
hyperbole,” there may be no liability unless the plaintiff proves “that
a statement is factually based and thus capable of a defamatory
meaning.”187
3. Abuse Of Trust
Patient-oriented social media sites may also present
opportunities for others to prey on patients and their families, for
example, by individuals misrepresenting their medical credentials, or
lack thereof.188 This can also include doctors or other healthcare
workers who are looking for individuals to sign up for clinical studies.
Rather than going through standard channels, doctors can come to
these social media sites to find a consolidated and interested
population with disclosed medical histories and conditions so that
they can find the best-suited individuals for their trials. A number of
clinical trials have already been staffed through contacting patients
via POSOMS.189 And while the FDA has specific rules for trial

183. Nanoviricides, Inc. v. Seeking Alpha, Inc., No. 151908/2014, 2014 WL 2930753
(N.Y. Sup. June 26, 2014); Biomatrix Corp., et al. v. Costanzo, et al., Docket No. BER-L-670-00
(Superior Court of New Jersey, Bergen County); Eric Niiler, Internet Chat Damages
Biotechnology Stocks, NATURE BIOTECHNOLOGY (2000), available at http://www.nature.com/
nbt/journal/v18/n10/full/nbt1000_1030b.html; Aaron Elstein, Judge Rules Online Postings
About Biomatrix Were Libel, WALL ST. J. (Aug. 3, 2000), available at http://www.wsj.com/
articles/SB965239740373615064.
184. E.g., Zeran v. America Online, Inc., 129 F.3d 327, 330 (4th Cir. 1997), cert. denied,
524 U.S. 937 (1998) (ruling that Section 230 of the Communications Decency Act “creates a
federal immunity to any cause of action that would make service providers liable for
information originating with a third-party user of the service.”); see also Barrett v. Rosenthal, 40
Cal. 4th 33 (2006).
185. 47 U.S.C. § 230(c)(1) (2012) (“No provider or user of an interactive computer service
shall be treated as the publisher or speaker of any information provided by another information
content provider.”).
186. Doe v. Cahill, 884 A.2d 451, 466 (Del. 2005).
187. Id. at 467-68 n.78.
188. Chretien & Kind, supra note 169.
189. Melanie Swan, Emerging Patient-Driven Health Care Models: An Examination of
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recruitment, they are not geared to online recruitment,190 and may or
may not clearly be applied.191
Even worse, snake-oil salesmen might present themselves as
legitimate pharmaceutical representatives or medical professionals to
sell useless or even harmful concoctions to the unassuming public
within what seems to them, to be a protected environment.192
In general, doctors and others trolling for bodies for their trials
should not do so anonymously, particularly when their perceived lack
of duty to someone else’s patient might result in them choosing
individuals who are best for the trial, although not necessarily
pointing out trials that are best for the individuals. Further, patients,
who might otherwise not sign up for clinical trials unless they were
presented to them by their trusted physician, may sign up for trials
that might not be in their best interests when approached online. In
some instances, a patient may sign up for what they perceive to be a
legitimate IRB approved trial, when in reality it is an ad hoc trial by
an unregulated body.
Additionally, concerns should be raised given that
pharmaceutical representatives or their paid agents can promote,
under the anonymity provided by the internet, their product, promote
off label use, disparage competing products, and use other marketing
tactics without disclosing their conflicts of interest. Even overtly,
patients may be influenced by directed marketing to choose one drug
over another. Pharmaceutical companies have made substantial efforts
in these areas, including, for example, conversational marketing (i.e.,
to make online friends and then turn those friends into customers) and
efforts to create online threads lead by peer influencers.193 In some
instances, patients are not even interacting with real individuals but

Health Social Networks, Consumer Personalized Medicine and Quantified Self-Tracking, 6
INT’L J. ENVTL RES. & PUBLIC HEALTH 492 (2009).
190. Jim Gearheart, Clinical Trial Recruitment Using Social Media is Growing, 5
QUORUM REVIEW IRB (Mar. 5, 2015), available at http://www.quorumreview.com/blog/2015/
03/05/clinical-trial-recruitment-social-media-growing/.
191. Kristen Snipes, Rho Regulatory Considerations for Using Social and Digital Media in
Clinical Trial Patient Recruitment, CLINICAL INFORMATICS NEWS (May 26, 2015), available at
http://www.clinicalinformaticsnews.com/2015/3/26/regulatory-considerations-using-socialdigital-media-clinical-trial-patient-recruitment.html.
192. Bradford W. Hesse et al., Social Participation in Health 2.0, 43 COMPUTER 45
(2010).
193. Manon Niquette, The Exploitation of “Sicko-Chatting” by the Pharmaceutical
Industry: A Strategy for the Normalization of Drug Use, SCIENTIFIC PUBLICATIONS OF THE
HUMANITIES AND SOCIAL SCIENCES UNIVERSITY OF LILLE (2013), available at http://hal.univlille3.fr/hal-00835818v2.
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rather artificial intelligence software aimed at creating new
customers.194 The extent of pharmaceutical representation on these
sites is unknown, as is the extent that pharmaceuticals promote
openly, or using sock puppets,195 their products.196
Finally, the aggregation of lay-minded patients on these website
can influence policy, regulation and crowdsourced funded research
both positively, and potentially negatively, if the lay-minded patients
are taken advantage of; each privately run POSOM potentially is its
own institution with its “own leadership, goals and agenda.”197
a. Regulation Of Patient Oriented Social Media Sites
All these concerns notwithstanding, the FDA has been loath to
substantively regulate social media in general198 and specifically as it
relates to pharmaceutical advertising.199 Social media is actually
already subject to some diverse sets of regulation. For example, on
standard social media sites, many non-pharmaceutical ads are
regulated via the FTC, financial communications with customers via
social media is regulated by the Financial Industry Regulatory
Authority, and the National Labor Relations Board provides
regulation regarding employer restrictions on access to social
media.200
However, like their efforts to regulate mobile medical
applications as devices, the FDA should similarly regulate broader
aspects of social media, particularly when those aspects of social
media as designed specifically for use in healthcare and health
delivery. While the FDA held public hearings in 2009 on issues

194. A similar example can be found from disclosures from the Ashley Madison website.
See, e.g., Annalee Newitz, How Ashley Madison Hid Its Fembot Con From Users and
Investigators, GIZMODO (Sept. 8, 2015), available at http://gizmodo.com/how-ashley-madisonhid-its-fembot-con-from-users-and-in-1728410265.
195. Chelsea Peters, Whole Foods, Unwholesome Practices: Will Sock Puppeteers Be Held
Accountable for Pseudonymous Web Postings, 5 SHIDLER J.L. COM. & TECH. 4, 5 (2008).
196. Greene et al., supra note 132.
197. Swan, supra note 189.
198. Venkatesh Shankar & Jiaoyang (Krista) Li, Leveraging Social Media in the
Pharmaceutical Industry, in INNOVATION AND MARKETING IN THE PHARMACEUTICAL
INDUSTRY 477 (Min Ding et al. eds., 2014).
199. U.S. Food and Drug Admin., For Industry: Using Social Media, ABOUT FDA (Oct.
29,
2014),
available
at
http://www.fda.gov/AboutFDA/CentersOffices/
OfficeofMedicalProductsandTobacco/CDER/ucm397791.htm.
200. Jon Poracro, Social Media Laws and Regulations You Should Know, METIA (Aug. 26,
2011), available at http://www.metia.com/seattle/john-porcaro/2011/08/social-media-laws-andregulations-you-should-know/.
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relating to promotional speech through social media,201 it has only
very recently released very limited guidance relating to discussing
pharmaceuticals on social media sites. In the interim, while the FDA’s
Office of Prescription Drug Promotion, formerly known as the
Division of Drug Marketing, Advertising, and Communications,
whose goal is to:
To protect the public health by assuring prescription drug
information is truthful, balanced and accurately communicated.
This is accomplished through a comprehensive surveillance,
enforcement and education program, and by fostering better
communication of labeling and promotional information to both
202
healthcare professionals and consumers.

In fact, the FDA has sent out only one regulatory action letter to
a pharmaceutical company where social media was the basis for the
offensive action in the years between 2008 and 2013.203 The only real
substantive guidance provided by the FDA in relation to social media
sites relates to correcting false information online – in short there is
no duty to correct online misinformation and traditionally,
pharmaceuticals have steered clear of correcting misinformation for
fear of backlash from the FDA. 204 The new guidance however also
allows companies the right to correct misinformation, provided that
the correction is “relevant and responsive,” “limited and tailored,”
“non-promotional,” and “accurate.”205 With this burden, it is unclear
how many pharmaceutical companies will take the opportunity to

201. U.S. Food and Drug Admin., Public Hearing on Promotion of FDA-Regulated
Medical Products Using the Internet and Social Media Tools, ABOUT FDA (Nov. 27, 2015),
available
at
http://www.fda.gov/AboutFDA/CentersOffices/
OfficeofMedicalProductsandTobacco/CDER/ucm184250.htm.
202. U.S. Food and Drug Admin., The Office of Prescription Drug Promotion, ABOUT
FDA
(Oct. 23, 2015) available at http://www.fda.gov/AboutFDA/CentersOffices/
OfficeofMedicalProductsandTobacco/CDER/ucm090142.htm.
203. Mark S. Senak, FDA Communications Oversight in a Digital Era 2008-2013,
EYEONFDA (Apr. 2013), available at http://www.eyeonfda.com/wp-content/uploads/2013/03/
FDA-Communications-Oversight-in-a-Digital-Era1.
204. See, e.g., Policy and Medicine, FDA Social Media Guidance: Correcting Independent
Third-Party Misinformation About Prescription Drugs and Medical Devices, POLICY AND
MEDICINE (June 18, 2014), available at http://www.policymed.com/2014/06/fda-social-mediaguidance-correcting-independent-third-party-misinformation-about-prescription-drugs-andmedical-devices.html (“Previously, companies have struggled with the best way to approach this
type of online misinformation. FDA’s Guidance provides clarity”).
205. U.S. Food & Drug Admin., Guidance for Industry: Internet/Social Media Platforms:
Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical
Devices, U.S. FOOD AND DRUG ADMIN. (June 2014), http://www.fda.gov/downloads/drugs/
guidancecomplianceregulatoryinformation/guidances/ucm401079.pdf.
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correct misinformation when they are legally safer to not say
anything. Note: there is also guidance for pharmaceuticals with
relation to microblogging.206
Other governmental agencies are also interested in some aspects
of POSOMS, including for example the FTC’s interest in the patient
privacy aspects related to patient data that is collected and catalogued
on many of these sites.207
The lack of FDA and other governmental oversight of POSOMS
will become increasingly problematic as both industry208 and
regulators themselves209 look to POSOMS as sources of
crowdsourced, user generated data for use in research and
development of medicine and other health-related technologies.
b. Patient Oriented Social Media Sites And Data
Creation And Collection
Obviously, POSOMS do not only help patients and their
families, other stakeholders benefit substantially from the data that
can be mined from these websites. Patients on these sites should be
wary: “When something online is free, you’re not the customer,
you’re the product.”210 Patientslikeme.com, and presumably other
similar social media websites make money by selling personal and
potentially private information.211,212 Even when they are not outright
206. Id.
207. Fed. Trade Comm’n, FTC Announces Agenda, Panelists for Upcoming Seminar on
Privacy Implications of Consumer Generated and Controlled Health Data, FED. TRADE
COMM’N PRESS RELEASES (May 1, 2014), available at http://www.ftc.gov/news-events/pressreleases/2014/05/ftc-announces-agenda-panelists-upcoming-seminar-privacy.
208. Jennifer Levin, AstraZeneca and PatientsLikeMe Announce Global Research
Collaboration, FIERCEBIOTECH (April 14, 2015), available at http://www.fiercebiotech.com/
press-releases/astrazeneca-and-patientslikeme-announce-global-research-collaboration.
209. Thomas Sullivan, PatientsLikeMe Teams With FDA To Explore Patient-Reported
Adverse Events, POLICY AND MEDICINE (July 9, 2015), available at http://www.policymed.com/
2015/07/patientslikeme-teams-with-fda-to-explore-patient-reported-adverse-events.html.
210. Jonathan Zittrain, The Future of the Internet and How to Stop It, HARVARD LAW
BLOGS (Mar. 21, 2012), http://blogs.law.harvard.edu/futureoftheinternet/2012/03/21/memepatrol-when-something-online-is-free-youre-not-the-customer-youre-the-product/.
211. PatientsLikeMe, Does PatientsLikeMe Sell My Information?, PATIENTSLIKEME
(2014), available at https://support.patientslikeme.com/hc/en-us/articles/201245770-DoesPatientsLikeMe-sell-my-information- (“The data and text you enter in and around the shared
parts of the site (e.g., on your profile, in the forum, symptom or treatment reports) may be
shared or sold in aggregate to partners.”).
212. Jim Edwards, PatientsLikeMe is More Villain than Victim in Patient Data
“Scrapping” Scandal,
CBS MONEYWATCH (Oct. 19, 2010), available at http://
www.cbsnews.com/news/patientslikeme-is-more-villain-than-victim-in-patient-data-scrapingscandal/ (“Here’s what type of data PatientsLikeMe scrapes from its own site for its clients:
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selling data, other companies may be scraping (i.e., “collecting online
data from social media and other Web sites in the form of
unstructured text . . . also known as site scraping, web harvesting and
web data extraction”)213 personal data from these sites.214
POSOMs are incentivized to get as many patients as possible to
sign up and eventually even disclose their health-related data, as they,
their corporate consumers and the patients themselves can benefit
from the network effects resulting from greater participants.215
PatientsLikeMe, founded in 2004, is one of the more popular
patient oriented social media sites. With more than a quarter of a
million members and 2000 health conditions, the site was noted in
2007 as a company that will change the world.216 The site is
configured to allow patients with similar diseases connect with their
peers to share information. And like many of the mHealth apps
described above, PatientsLikeMe.com and other similar sites
empower patients to learn more and do more about their health
condition.
This patient empowerment is part of a general trend that includes
crowdsourcing, citizen science.217 uBiome (a citizen science
startup)218 and other forms of participant led research — sometimes
known as prosumption (the simultaneous production and consumption
of information)219 — can empower the patient, subject, or non-health
Condition/disease information, including diagnosis date, first symptom information, and family
history; Treatment regimens, including treatment start dates, stop dates, dosages, and side
effects; Symptoms experienced, including severity and duration; Laboratory results (e.g. CD-4
count, Viral Load); Biographical information, including photo, bio, gender, age, location (city,
state & country), and general notes; Genetic information, including information on individual
genes and/or entire genetic scans”).
213. Bogdan Batrinca & Philip C. Treleaven, Social Media Analytics: A Survey of
Techniques, Tools and Platforms, 30 AI & SOC’Y 89 (2015).
214. Julia Angwin & Steve Stecklow, ‘Scrapers’ Dig Deep for Data on Web, WALL ST. J.
(Oct.
12,
2010),
available
at
http://www.wsj.com/news/articles/
SB10001424052748703358504575544381288117888?mod=WSJ_0_0_WP_2715_
RIGHTTopCarousel_1&mg=reno64wsj&url=http%3A//online.wsj.com/article/
SB10001424052748703358504575544381288117888.html%3Fmod%3DWSJ_0_0_WP_2715_
RIGHTTopCarousel_1.
215. Frost & Massagli, supra note 130.
216. Erick Schonfeld & Chris Morrison, The Next Disruptors, CNN MONEY (Aug. 22,
2007), available at http://money.cnn.com/magazines/business2/business2_archive/2007/09/01/
100169862/index.htm.
217. Rick Bonney et al., Citizen Science: A Developing Tool for Expanding Science
Knowledge and Scientific Literacy, 59 BIOSCIENCE 977 (2009).
218. UBIOME, http://ubiome.com/ (last visited Nov. 1, 2015).
219. David Beer & Roger Burrows, Consumption, Prosumption and Participatory Web
Cultures: An Introduction, 10 J. CONSUMER CULTURE 3 (2010); George Ritzer & Nathan
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practitioner stakeholder to partially direct, control or simply have a
greater degree of input in the analysis than they otherwise mite via the
classical investigator led research (ILR) paradigm.220
Some have argued that these non-commercial, disease-oriented,
and patient-controlled studies provide a greater likelihood of resulting
in real actionable changes for patients and their families.
Additionally, without the profit limitations of large drug corporations,
patient-directed research allows for research in even unprofitable or
otherwise marginalized areas.
In fact, the use of POSOMS promises to provide scientists with
new and novel ways of collecting heretofore hard-to-collect data
related to diseases, including for example, otherwise very expensive,
hard-to-find, and hard-to-collect data on off-label usage of
pharmaceuticals.221 This is not necessarily a bad thing.222 Some would
argue that collecting data directly from patients, often in real time as
they interact with the social media site, results in fewer concerns
about the veracity of data,223 particularly as a result of memory
bias.224
Moreover, the use of patient reported data, particularly from
POSOMS, can make expensive and time consuming off-label and
new-use studies for existing drugs feasible.225 POSOMS have also
been helpful in locating otherwise lost patients in long-term
longitudinal studies.226
There are some downsides to patients collectively becoming
more involved in their research, particularly outside of normal

Jurgenson, Production, Consumption, Prosumption: The Nature of Capitalism in the Age of the
Digital “Prosumer”, 10 J. CONSUMER CULTURE 13 (2010).
220. Effy Vayena & John Tasioulas, The Ethics of Participant-Led Biomedical Research,
31 NATURE BIOTECHNOLOGY 786 (2013).
221. Jeana Frost et al., Patient-Reported Outcomes as a Source of Evidence in Off-Label
Prescribing: Analysis of Data From PatientsLikeMe, 13 J. MED. INTERNET RES., Jan.—Mar.
2011.
222. See Dina Fine Maron, Your Medical Records May Unlock Disease Secrets for All,
SCI. AM. (August 6, 2015), available at http://www.scientificamerican.com/article/yourmedical-records-may-unlock-disease-secrets-for-all/.
223. Paul Wicks et al., Accelerated Clinical Discovery Using Self-Reported Patient Data
Collected Online and a Patient-Matching Algorithm, 29 NATURE BIOTECHNOLOGY 411 (2011).
224. Jeana H. Frost, The Case for Using Social Media to Aggregate Patient Experiences
with Off-Label Prescriptions, 11 EXPERT REV. PHARMACOECONOMICS & OUTCOMES RESEARCH
371 (2011).
225. Frost, supra note 221.
226. Allison Cook Reaves & Diana W. Bianchi, The Role of Social Networking Sites in
Medical Genetics Research, 161 AM. J. MED. GENETICS PART A 951 (2013).
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operating parameters: for example, in one case a large cohort from a
study colluded on Patientslikeme.com to determine who was
receiving a placebo and who was receiving the actual drug over the
course of a double-blind study, this sort of revelation can seriously
harm the integrity of an expensive drug study.227
Other concerns include issues of selection bias (data population
does not accurately reflect the actual broader patient population),
confounding (misleading associations resulting from, for example, a
third unrelated piece of information) and information bias (related to
systematic errors associated with the collection of the data), resulting
with, at minimum, that patient provided data collected through
POSOMS out to be read and interpreted with a certain degree of
caution.228 Moreover, patient-led research lacks many of the built-in
checks and balances of institutional-based research. For example,
patient-led research typically does not carry the same ethical
oversight; institutional review boards (IRBs) are typically lacking or
privately financed in citizen science endeavors. (Some have also
suggested that the same model that provides for patient led research,
could also provide for patient-led or otherwise crowdsourced ethical
review boards.229)
Further, patient led research includes other ethical and scientific
concerns including, lack of state recognition and support, issues
related to the veracity and reliability of self-reported results,230
general concerns with self-experimentation, inability to appreciate the
risks of their own research, and the general blurring of the lines
between researchers, subjects and sponsors, potentially a lack of
openness and transparency and lack of informed consent.231 Some
have further argued that this patient-led “disobedience” against the
institutionalized research system, while enabling rapid dissemination
of research results and perhaps a greater degree of self-knowledge,
nevertheless wades into ethically murky areas by short-circuiting

227. Virginia Hughes, Social Storm: The Drug Industry is Struggling to Find Ways of
Engaging with Consumers on Social Media, 33 NATURE BIOTECHNOLOGY 14 (2015).
228. A. Cecile JW Janssens & Peter Kraft, Research Conducted Using Data Obtained
Through Online Communities: Ethical Implications of Methodological Limitations, 9 PLOS
MED. (2012).
229. See, e.g., Melanie Swan, Scaling Crowdsourced Health Studies: The Emergence of a
New Form of Contract Research Organization, 9 PERSONALIZED MED. 223 (2012).
230. Frost, supra note 221.
231. Effy Vayena, Opinion: Unconventional Standards, THE SCIENTIST (Mar. 13, 2013),
available
at
http://www.the-scientist.com/?articles.view/articleNo/34690/title/Opinion—Unconventional-Standards/.
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standard pathways to review ethical concerns as well as informed
consent.232
c. Suggestions For Regulation
With nearly 300,000 members on Patientslikeme.com alone,233
not to mention the tens if not hundreds of other sites, actively policing
these sites is not really feasible.
Nevertheless, patient oriented social media sites need some sort
of regulatory oversight, not least because they involve a captured,
desperate, and perhaps naïve community that can be easily taken
advantage of.
As described above, concerns particularly come into play when
patients are approached by health care workers or their doctors on
these types of sites. These concerns are particularly apropos when
these approaches are through thread initiators, individuals who tend to
have substantial sway on these social media sites.234 While some
might argue that these sorts of interactions are important to humanize
the doctors and open up otherwise stifled channels,235 others are wary
of inappropriate and/or illegal patient-doctor relationships,236, 237 with
some setting some important ground rules for these types of
relationships.238 In particular, social media interactions between
doctors and patients raise these and other concerns: whether a
doctor’s particular opinion in one of these forums, intended narrowly
may be misconstrued in a broader sense; difficulties in maintaining
patient and colleague privacy; and whether the relaxed atmosphere

232. Paul Wicks et al., Subjects No More: What Happens When Trial Participants Realize
They Hold the Power?, BRIT. MED. J. (2014), http://www.bmj.com/content/348/
bmj.g368.full.pdf.
233. Patients, PATIENTSLIKEME, http://www.patientslikeme.com/patients (last visited
Nov. 1, 2015).
234. Kordzadeh et al., supra note 128.
235. Sachin H. Jain, Practicing Medicine in the Age of Facebook, 361 NEW ENG. J. MED.
649 (2009).
236. Lori Wiener et al., To Friend or Not to Friend: The Use of Social Media in Clinical
Oncology, 8 J. ONCOLOGY PRACTICE 103 (2012).
237. Paul H. Keckley & Michelle Hoffmann, Social Networks in Health Care:
Communication, Collaboration and Insights, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
(2010),
https://www.ucsf.edu/sites/default/files/legacy_files/US_CHS_2010SocialNetworks_
070710.pdf.
238. Manik S. Kadam & Murtaza M. Junaid Forooque, Usage of Social Networking
amongst Health-Care Professional for Dissemination of Medical Knowledge and Community
Service, RESEARCH GATE (June 16, 2015), available at http://www.researchgate.net/publication/
277557656_Usage_of_Social_Networking_amongst_Health-Care_Professional_for_
Dissemination_of_Medical_Knowledge_and_Community_Service.
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may lead a professional to misrepresent science, medicine or their
institutions or the nature of their degree and/or specialty. Nevertheless
these sites remain practical additions to regular health care visits, with
physician participation online most rewarding for underserved
communities and geographically mobile patients.239
Other issues related to POSOMs relate generally to the
generation and use of the patient and personal data on the websites.
Who owns the data? Who is responsible for the accuracy of the
patient’s data and any data presented to the patient through the
website, other members (e.g., patients and family) participating on the
website and/or third parties? Who can access the data? Who is
responsible for protecting and validating the data?240
In contrast to MMAs, a technological solution may not be best.
In fact, with enforced proper disclosures, many of the concerns raised
become mute. The problem lies in enforcing that disclosure and/or
educating the often naïve consumer.
One solution might include a multi-tiered approach based on a
certification that could be displayed on the websites’ homepages.
Thus, whatever governmental agency or non-governmental group
takes it upon themselves to police these sites, that group/agency
would make it known immediately to all visitors whether or not the
site is in compliance with best practices or not. In addition to the
certification mark, a concerted effort ought to be made to inform the
doctors to educate their patients, if nothing else, to at least be wary
and suspicious of their online interactions, even in their perceived
safe environments of their online communities.
To this end, the policing body would be developed, perhaps in
conjunction with patient groups, industry groups and other related
agencies. Importantly, a set of best practices for all aspects of running
the website, taking into account the needs and concerns of all
stakeholders could be developed. This would include best practices
relating to health-care worker anonymity, anonymizing data,
advertising, selling data, patient interactions, physician interactions,
pharmaceutical industry interactions and other relevant areas of
concern. For example, physicians should be required to be nonanonymous with their credentials vetted. Similarly, pharmaceutical

239. Gemma Sinead Ryan, Online Social Networks for Patient Involvement and
Recruitment in Clinical Research, 21 NURSE RESEARCHER 35 (2013).
240. Wei Wan-Chu, Ethical Risks Inhabited in Social Networking Sites: A Case Study on
PatientslikeMe.com, INT’L PROC. COMPUTER SCI. & INFO. TECH. (2012), http://www.ipcsit.com/
vol45/049-ICIKM2012-M20007.pdf.
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companies and their agents would have to be clearly identified or risk
being banned from the site. Perhaps something akin to Amazon’s
Real Name Badge program in customer reviews.241 Additionally,
patients should have to be fully informed in a clear and industry-wide
consistent manner as to what happens to their data. Moreover, sites
should employ the necessary technologies to prevent the wholesale
scraping of data, as well as limiting non-member access to nonprivileged areas.
Best practices would be suggested industry wide with
certification seals from the oversight /policing group only provided to
those websites that subscribe to all the best practices. Perhaps the
same oversight/policing group could employ monitors to check up,
unannounced, on a semi regular basis to review protocols, obtain data
about problematic instances (e.g., an unidentified doctor, an
individual masquerading as a doctor, defamation, or promotion of offlabel uses by pharmaceuticals) and confirm that the website dealt with
these issues as per best practices and protocol.
National and/or regional IRBs should also be created, not only
would these be of value to many institutions that do not have the
knowledgebase to create their own multidisciplinary IRBs, but also
for citizen science resulting from patient oriented social media sites.
Currently, most sites have to rely on expensive and sometimes
ethically-conflicted paid-for services. Moreover the control and
ownership of any drugs or technologies resulting from the citizen
science or patient disclosures should be clearly explained to all
participants, such that the websites do not unknowingly or secretly
profit off of their member’s efforts.
CONCLUSION
This paper presents two different but very much related
emerging technologies: (1) mobile medical device applications that
take advantage of the growing complexity of every day devices, and
(2) patient oriented social media that builds off of the exponential
growth of Web 2.0.
Both of these technologies (as employed particularly to the
portion of the population with chronic diseases) can be extremely
valuable, not only in providing information, support and care to those
who need it, but also in efficiently creating data for the patients and

241. ABOUT BADGES, http://www.amazon.com/gp/help/customer/display.html/ref=cm_
dly_lnk?ie=UTF8&nodeId=14279681&pop-up=1 (last visited Nov. 1, 2015).
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their peers. Both technologies further serve to democratize what has
traditionally been a paternalistic area of medical care. And, both
technologies can be particularly helpful for the underserved and
underrepresented in society.
Both also present significant challenges in that they can be easily
abused, but not easily policed and regulated. To this end, this paper
takes two very different approaches, suggesting that MMAs be less
heavily regulated than they currently are, to promote innovation, and
that POSOMS be more heavily regulated to protect their patient
populations.
Many of the concerns raised with regard to MMAs can be better
resolved with technological solutions that limit error and protect
privacy. Whereas many of the concerns raised with regard to
POSOMS require human intervention and oversight and cannot easily
be addressed through implementing technological fixes.

